Document:

EX-10.15

 Confidential Treatment Requested by Vera Therapeutics, Inc. 

Pursuant to 17 C.F.R. § 200.83 
  

 Exhibit 10.15 

Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant
treats as private or confidential. Information that was omitted has been noted in this document with a placeholder identified by the mark “[***]”. 

Execution Copy 
 ASSET
PURCHASE AGREEMENT 
 This Asset Purchase Agreement (the “Agreement”) is made and entered into as of December 16,
2021 between Amplyx Pharmaceuticals, Inc., a Delaware corporation (the “Seller”), and Vera Therapeutics, Inc., a Delaware corporation (the “Buyer”). 

WHEREAS, on April 27, 2021 (the “Merger Date”) Seller became a wholly-owned subsidiary of Pfizer Inc.
(“Pfizer”) pursuant to an Agreement and Plan of Merger, dated April 12, 2001, among Pfizer, Appaloosa Merger Sub Inc. and the Seller (the “Pfizer-Amplyx Agreement”); 

WHEREAS, Seller is developing an anti-BKV monoclonal antibody referred to as “MAU868” for
the treatment of BKV disease pursuant to a License Agreement, dated August 26, 2019 (the “Novartis License”), between Novartis International Pharmaceutical AG (“Novartis”) and the Seller; and 

WHEREAS, Seller desires to sell to Buyer, and Buyer desires to acquire from Seller, all of Seller’s right, title and interest in and to
certain assets, including intellectual property rights, pertaining to MAU868 on the terms and subject to the conditions set forth herein. 

NOW, THEREFORE, in consideration of the foregoing and the representations, warranties, covenants and agreements contained herein, the parties
hereto hereby agree as follows: 
 ARTICLE I 

DEFINITIONS AND TERMS 

Section 1.1    Definitions. As used in this Agreement, the following terms shall have the meanings set forth
or as referenced below: 
 “Affiliate” shall mean, with respect to any Person, any other Person that directly or
indirectly, through one or more intermediaries, controls, is controlled by, or is under common control with, such Person at any time during the period for which the determination of affiliation is being made. For the purposes of this definition, the
word “control” (including, with correlative meaning, the terms “controlled by” or “under the common control with”) shall mean the actual power, either directly or indirectly through one or more intermediaries, to direct
or cause the direction of the management and policies of such Person, whether by the ownership of fifty percent (50%) or more of the voting stock or units of such Person, or by contract or otherwise. 

  

 Confidential Treatment Requested by Vera Therapeutics, Inc. 

Pursuant to 17 C.F.R. § 200.83 
  

 “Agreement” shall have the meaning set forth in the preamble. 

“Allocation” shall have the meaning set forth in Section 2.7. 

“Antibody” means (a) the fully human monoclonal antibody referred to as “MAU868” described more fully on
Exhibit A to the Novartis License, (b) the monoclonal antibodies claimed in the patent rights set forth on Exhibit C to the Novartis License, and (c) any [***]. 

“Assignment and Assumption Agreement” shall have the meaning set forth in Exhibit A. 

“Assumed Liabilities” shall have the meaning set forth in Section 2.4. 

“Business Day” shall mean any day other than a Saturday, a Sunday or a day on which banks in New York, New York and San
Francisco, California, United States of America are authorized or obligated by Law or executive order to close. 
 “Buyer”
shall have the meaning set forth in the preamble to this Agreement. 
 “Buyer Material Adverse Effect” shall have the
meaning set forth in Section 4.4. 
 “Closing” shall have the meaning set forth in Section 2.8(a). 

“Closing Date” shall have the meaning set forth in Section 2.8(a). 

“Collateral Source” shall have the meaning set forth in Section 6.6. 

“Confidentiality Agreement” shall mean the Confidentiality Agreement dated as of August 5, 2021, between Pfizer and
Buyer. 
 “European Regulatory Approval” means Regulatory Approval from the European Medicines Agency or any successor
entity thereto or the applicable Governmental Authority in any one of the five major European markets (France, Germany, Italy, Spain or the United Kingdom). 

“Excluded Assets” shall have the meaning set forth in Section 2.3. 

“FDA” shall mean the United States Food and Drug Administration and any successor agency(ies) or authority having
substantially the same function. 
 “First Commercial Sale” means the first sale of a Product to a Third Party for
distribution, use or consumption in such country after the Regulatory Approvals have been obtained for the Product in such country. For clarity, First Commercial Sale shall not include any sale or transfer of any Product prior to receipt of
Regulatory Approval, such as “treatment IND sales,” “named patient sales” and “compassionate use sales.” 

“Governmental Authority” shall mean any supranational, national, federal, state or local judicial, legislative, executive or
regulatory authority. 

  
 2 

  

 Confidential Treatment Requested by Vera Therapeutics, Inc. 

Pursuant to 17 C.F.R. § 200.83 
  

 “Governmental Authorizations” shall mean all licenses, permits, certificates
and other authorizations and approvals issued by the relevant Governmental Authority that are required to carry on the research activities conducted by Seller and its Affiliates using the Purchased Assets as of the date of this Agreement under the
applicable Laws. 
 “Governmental Order” shall mean any order, writ, judgment, injunction, decree, stipulation,
determination or award entered by or with any Governmental Authority. 
 “Income Taxes” mean the United States federal
income Tax and any state, local or non-U.S. net income Tax or any franchise or business Tax incurred in lieu of a Tax on net income. 

“Indemnified Party” shall have the meaning set forth in Section 6.3. 

“Indemnifying Party” shall have the meaning set forth in Section 6.3. 

“Indication” shall have the meaning set forth in Novartis License. 

“Intellectual Property Rights” shall mean and include all rights of the following types, which may exist or be created under
the laws of any jurisdiction in the world: (i) rights associated with works of authorship, including exclusive exploitation rights, copyrights, moral rights, and mask works; (ii) trademark and trade name rights and similar rights;
(iii) trade secret rights; (iv) Patents and industrial property rights; (v) other proprietary rights in intellectual property of every kind and nature; and (vi) all registrations, renewals, extensions, continuations, divisions,
or reissues of, and applications for, any of the rights referred to in clauses (i) through (vi) above. 
 “Law” shall
mean any federal, state, foreign or local law, common law, statute, ordinance, rule, regulation, code or Governmental Order. 

“Liabilities” shall mean any debts, liabilities or obligations, whether accrued or fixed, known or unknown, absolute or
contingent, matured or unmatured or determined or determinable. 
 “Lien” shall mean any lien, security interest, mortgage,
charge or similar encumbrance. 
 “Loss” or “Losses” shall have the meaning set forth in
Section 6.1(a). 
 “Merger Date” shall have the meaning set forth in the recitals. 

“Net Sales” shall have the meaning set forth in the Novartis License. 

“Novartis” shall have the meaning set forth in the recitals. 

“Novartis License” shall have the meaning set forth in the recitals. 

  
 3 

  

 Confidential Treatment Requested by Vera Therapeutics, Inc. 

Pursuant to 17 C.F.R. § 200.83 
  

 “Patent Assignment Agreement” shall have the meaning set forth in Exhibit A.

 “Patents” shall mean (a) all national, regional and international patents and patent applications, including
provisional patent applications and any and all rights to claim priority thereto; (b) all patent applications filed either from such patents, patent applications, or provisional applications or from an application claiming priority from either
of these, including divisionals, continuations, continuations-in-part, provisionals, converted provisionals, and continued prosecution applications; (c) any and all
patents that have issued or in the future issue from the foregoing patent applications ((a) and (b)), including utility models, petty patents, and design patents and certificates of invention; (d) any and all extensions or restorations by
existing or future extension or restoration mechanisms, including revalidations, reissues, re-examinations, and extensions (including any supplementary protection certificates and the like) of the foregoing
patents or patent applications or other patents resulting from post-grant proceedings ((a), (b), and (c)); and (e) any similar patent rights, including so-called pipeline protection or any importation,
revalidation, confirmation, or introduction patent or registration patent or patent of additions to any of such foregoing patent applications and patents. 

“Permitted Encumbrances” shall mean (a) all Liens [***]; or (b) such Liens and other imperfections of title [***].

 “Person” shall mean any individual, firm, corporation, partnership, limited liability company, trust, joint venture,
Governmental Authority or other legal entity or organization. 
 “Pfizer” shall have the meaning set forth in the recitals.

 “Pfizer-Amplyx Agreement” shall have the meaning set forth in the recitals. 

“Product” means any product in any dosage strength or formulation containing, incorporating or comprising an Antibody, either
alone or in combination with other agents. 
 “Purchased Assets” shall have the meaning set forth in Section 2.1, it
being understood that the Purchased Assets do not include the Excluded Assets. 
 “Regulatory Approval” shall have the
meaning set forth in Novartis License. 
 “Required Third Party Consent” shall have the meaning set forth in
Section 2.2(a). 
 “Retained Liabilities” shall have the meaning set forth in Section 2.5. 

“Royalty Term” shall have the meaning set forth in the Novartis License. 

“Seller” shall have the meaning set forth in the preamble to this Agreement. 

  
 4 

  

 Confidential Treatment Requested by Vera Therapeutics, Inc. 

Pursuant to 17 C.F.R. § 200.83 
  

 “Seller Material Adverse Effect” shall mean any change, effect, event,
circumstance, occurrence or state of facts that, individually or in the aggregate, would be reasonably likely to (a) be materially adverse to the ability of the Seller to perform its obligations hereunder, (b) materially impair the value
or the use of the Antibody and Purchased Assets, or (c) prevent, materially impede or delay the consummation of the transactions contemplated hereby other than any change, effect, event, circumstance, occurrence or state of facts relating to
(i) the economy or financial markets in general, (ii) the consummation of the transactions as contemplated by this Agreement, (iii) [***], (iv) [***], (v) [***], and (vi) [***]. 

“Tax” or “Taxes” means any federal, state, local and non-U.S. taxes,
including without limitation, income, gross receipts, capital stock, franchise, profits, withholding, social security, unemployment, disability, real property, ad valorem/personal property, stamp, excise, occupation, sales, use, transfer, value
added, alternative minimum, estimated, license, severance, registration, natural resources, environmental, customs duties, escheat, fringe benefits, goods and services, intangible, inventory, land, recording, rent, windfall profits, capital gains,
capital stock, franchise, payroll, employment, property, add-on minimum, and other taxes imposed by a Governmental Authority, including any interest, penalty or addition thereto, whether disputed or not, and
shall include any liability for such amounts as a result of being a member of a combined, consolidated, unitary or affiliated group (including pursuant to Treasury Regulation Section 1.1502-6 or
comparable provisions of state, local or non-U.S. tax law) and including any liability for taxes as a transferee or successor, by contract or otherwise. 

“Tax Action” shall have the meaning set forth in Section 5.4(b). 

“Third Party” shall mean any Person other than Seller, Buyer or an Affiliate of either Seller or Buyer. 

“Third Party Claim” shall have the meaning set forth in Section 6.4(a). 

“VAT” shall have the meaning set forth in Section 5.4(a). 

Section 1.2    Other Definitional Provisions. 

(a)    The words “hereof”, “herein”, “hereto” and
“hereunder” and words of similar import, when used in this Agreement, shall refer to this Agreement as a whole and not to any particular provision of this Agreement. 

(b)    The definitions contained in this Agreement are applicable to the singular as well as the plural forms of such
terms. 
 (c)    The terms “dollars” and “$” shall mean United States dollars. 

(d)    The term “including” shall mean “including, without limitation” and the words
“included” and “include” shall have corresponding meanings. 

  
 5 

  

 Confidential Treatment Requested by Vera Therapeutics, Inc. 

Pursuant to 17 C.F.R. § 200.83 
  

 (e)    When a reference is made in this Agreement to an Article, a
Section, Exhibit or Schedule, such reference shall be to an Article of, a Section of, or an Exhibit or Schedule to, this Agreement unless otherwise indicated. 

(f)    When a reference is made in this Agreement to the terms of the Novartis License, such reference shall be to the
Novartis License as is in effect on the date hereof and not as it may be subsequently amended or changed. 
 ARTICLE II 

PURCHASE AND SALE 

Section 2.1    Purchase and Sale of the Purchased Assets. Upon the terms and subject to the conditions set
forth herein, effective at the Closing, Seller shall sell, convey, assign and transfer, and hereby sells, conveys, assigns and transfers to Buyer, and Buyer shall purchase, acquire and accept, and hereby purchases, acquires and accepts from the
Seller, free and clear of all Liens, other than Permitted Encumbrances, all of the Seller’s right, title and interest in and to the following assets (collectively, the “Purchased Assets”): 

(a)    the investigational new drug application filed with the FDA for authorization for the investigation of the Antibody
listed on Schedule 2.1(a) (“Seller IND”); 
 (b)    the development and regulatory files,
documentation, data, results and other electronic records identified on Schedule 2.1(b) (“Seller Development and Regulatory Documentation”); 

(c)    the contracts to which Seller is a party that are [***], including, in any event, the contracts identified on
Schedule 2.1(c) (“Seller Contracts”); 
 (d)    the Patents listed on Schedule 2.1(d) (“Seller
Patents”); and 
 (e)    the chemical and biological materials listed on Schedule 2.1(e) (“Seller
Product Inventory”). 
 Section 2.2    Consents. 

(a)    Buyer acknowledges and agrees that certain Purchased Assets may not be assignable or transferable without the
consent of a Third Party (each, a “Required Third Party Consent”), and, at or prior to the Closing Date, such consents have not been obtained. After the Closing Date, Seller will [***] to obtain those Required Third Party Consents
[***]; provided, however, that [***]. Upon obtaining the Required Third Party Consent such Purchased Asset shall be transferred and assigned to, and assumed by, Buyer hereunder. 

(b)    With respect to any Purchased Asset that is subject to a Required Third Party Consent that has not been obtained
pursuant to Section 2.2(a), after the Closing and [***] (i) [***] and (ii) [***], the parties hereto shall [***]. 

  
 6 

  

 Confidential Treatment Requested by Vera Therapeutics, Inc. 

Pursuant to 17 C.F.R. § 200.83 
  

 (c)    Buyer agrees that [***]. Buyer further agrees that [***]. 

Section 2.3    Excluded Assets. Notwithstanding any provision in this Agreement, Buyer is not purchasing any
asset that is not expressly identified on Schedule 2.1 (the “Excluded Assets”) including: 

(a)    [***]; 

(b)    [***]; and 

(c)    [***]. 

Section 2.4    Assumption of Certain Liabilities. Upon the terms and subject to the conditions of this
Agreement, Buyer agrees, effective at the Closing, to assume all Liabilities of the Seller and its Affiliates, of any kind, character or description, whether accrued, absolute, contingent or otherwise, [***] (other than Retained Liabilities), to the
extent (but only to the extent) arising out of or relating to the Purchased Assets (collectively, the “Assumed Liabilities”). 

Section 2.5    Retained Liabilities. Notwithstanding any provision in this Agreement, Seller and its
Affiliates shall retain and be responsible for the following (collectively, the “Retained Liabilities”): 

(a)    the Liabilities of Seller set forth on Schedule 2.5(a); 

(b)    all Liabilities of Seller, or any member of any consolidated, affiliated, combined or unitary group of which Seller
is or has been a member, for Income Taxes attributable to taxable periods, or portions thereof, ending on or before the Closing Date; 

(c)    all Liabilities for which Seller or its Affiliates expressly has responsibility pursuant to the terms of this
Agreement; and 
 (d)    all Liabilities to the extent arising out of or relating to Excluded Assets. 

Section 2.6    Consideration. 

(a)    Upfront Payment. In partial consideration of the sale and transfer of the Purchased Assets, Buyer shall pay
Seller five million dollars ($5,000,000) in cash at the Closing (the “Upfront Payment”). 

(b)    Milestone Payments. In partial consideration of the sale and transfer of the Purchased Assets, Buyer shall
make the following one-time cash payments to Seller upon achievement of the corresponding milestone event set forth below (the “Milestone Payments”): 

(i)    [***] upon [***]; 

(ii)    [***] upon [***]. 

  
 7 

  

 Confidential Treatment Requested by Vera Therapeutics, Inc. 

Pursuant to 17 C.F.R. § 200.83 
  

 The aggregate Milestone Payments under this Section 2.6(b) shall not exceed seven million dollars
($7,000,000), regardless of the number of times any milestone event has been achieved or the number of Products achieving such milestone event. Buyer shall notify Seller in writing within [***] after the achievement of the applicable milestone
event. Seller shall invoice Buyer for the corresponding Milestone Payment, and Buyer shall make such Milestone Payment to Seller within [***] after receiving such invoice from Seller. 

(c)    Earn-out. In partial consideration of the sale and transfer of the
Purchased Assets, on a Product-by-Product and country-by-country basis, commencing upon
the First Commercial Sale of a particular Product in a particular country, until the expiration of the Royalty Term for such Product in such country, Buyer shall pay to Seller an earnout equal to [***] of the aggregate Net Sales of such Product in
such country. 
 (d)    Earn-out Report and Payment. Within [***] after
the end of each calendar quarter, commencing with the first calendar quarter in which there are any Net Sales of a Product anywhere in the world, Buyer shall provide Seller with a report setting forth the amount of Net Sales of the Products on a country-by-country basis and the earnout payable on such Net Sales pursuant to Section 2.6(c). [***], Buyer shall pay the applicable royalty payments due to Seller for
such calendar quarter. All payments under this Agreement will be payable in US Dollars. When conversion of payments from any foreign currency is required to be undertaken by Buyer, the US Dollar equivalent will be calculated using Buyer’s
then-current standard exchange rate methodology as applied in its external reporting. If there is no standard exchange rate methodology applied by Buyer in its external reporting in accordance with its Accounting Standards, then any amount in a
currency other than US Dollars shall be converted to US Dollars using the exchange rate most recently quoted in the Wall Street Journal in New York as of [***]. Without limiting any other rights or remedies available to the Seller hereunder,
if Buyer [***]. 
 (e)    Records and Audits. Buyer will keep, and will cause its Affiliates to keep, complete,
true and accurate books and records in accordance with its Accounting Standards in relation to Net Sales and the earnouts payable to Seller under section 2.6(c), above. Buyer will [***] and in the event such audit reveals an underpayment or
overpayment by the Buyer, the underpaid or overpaid amount will be settled promptly. 

Section 2.7    Allocation of the Consideration. All considerations paid by Buyer to Seller pursuant to
Section 2.6 shall be allocated for Tax purposes among the Purchased Assets as mutually agreed to by the parties (the “Allocation”). Seller and Buyer agree not to take a position on any Income Tax return, before any Governmental
Authority or in any judicial proceeding that is inconsistent with the Allocation. 
 Section 2.8    Closing.

 (a)    On the terms and subject to the conditions of this Agreement, the closing of the transactions contemplated by
this Agreement (“Closing”) shall take place at the offices of Pfizer Inc., 235 East 42nd Street, New York, New York 10017-5755 (or, if agreed by the parties, electronically through the exchange of documents), at 12:00 p.m. (EST) on
the date hereof, or at such other time and place as the parties hereto shall agree (the “Closing Date”). At Closing, there shall be an exchange of funds and documents. For purposes of this Agreement, unless otherwise agreed in
writing by the parties, Closing shall be treated as if it occurred as of 12:01 a.m. on the Closing Date. 

  
 8 

  

 Confidential Treatment Requested by Vera Therapeutics, Inc. 

Pursuant to 17 C.F.R. § 200.83 
  

 (b)    At the Closing, Seller shall deliver, or cause to be delivered, to
Buyer the instruments and documents set forth in Exhibit A, in each case in a form reasonably acceptable to Buyer. 

(c)    At the Closing, Buyer shall deliver, or cause to be delivered, to Seller the following: (i) the Upfront
Payment, by wire transfer in immediately available funds, and (ii) the instruments and documents set forth in Exhibit B, in each case in a form reasonably acceptable to Seller. Seller shall provide wire transfer instructions to the Buyer
at least [***] prior to the Closing. 
 ARTICLE III 

REPRESENTATIONS AND WARRANTIES OF SELLER 

Except as set forth in Seller’s Disclosure Schedules, Seller represents and warrants to Buyer as follows: 

Section 3.1    Organization. Seller is a corporation duly organized, validly existing and in good standing
under the Laws of the State of Delaware. 
 Section 3.2    Authority; Binding Effect. 

(a)    Seller has all requisite corporate power and authority to execute and deliver this Agreement and to perform its
obligations hereunder. The execution and delivery by Seller of this Agreement and the performance by Seller of its obligations hereunder have been, or will have been at the Closing, duly authorized by all requisite corporate action. 

(b)    This Agreement has been duly executed and delivered by Seller and, assuming the due authorization, execution and
delivery by Buyer of this Agreement, constitutes a valid and binding obligation of Seller, enforceable against it in accordance with its terms, except as enforcement may be limited by bankruptcy, insolvency, reorganization, moratorium or similar
laws affecting creditors’ rights generally or by general principles of equity (regardless of whether enforcement is sought in a proceeding in equity or law). 

Section 3.3    Non-Contravention. The execution, delivery and
performance by Seller of this Agreement, and the consummation of the transactions contemplated hereby do not and will not (i) violate any provision of the certificate of incorporation or bylaws of Seller; (ii) assuming receipt of all
Required Third Party Consents, conflict with, or result in the breach of or constitute a default under, any contract, agreement, lease or license to which Seller is a party and which relates exclusively to the Purchased Assets or (iii) assuming
compliance with the matters set forth in Section 3.4 and Section 4.5, violate or result in a breach of or constitute a default under any Law or other restriction of any Governmental Authority to which the Seller is subject; except, with
respect to clauses (ii) and (iii), for any violations, breaches, conflicts or defaults, that have not had, and would not reasonably be expected to have, individually or in the aggregate, a Seller Material Adverse Effect. 

  
 9 

  

 Confidential Treatment Requested by Vera Therapeutics, Inc. 

Pursuant to 17 C.F.R. § 200.83 
  

 Section 3.4    Governmental Authorization. The execution and
delivery by Seller of this Agreement and the consummation of the transactions contemplated hereby do not require any consent or approval of any Governmental Authority, except for consents or approvals, the failure of which to obtain has not had, and
would not reasonably be expected to have, individually or in the aggregate, a Seller Material Adverse Effect. 

Section 3.5    Title to Purchased Assets. The Seller owns, leases or has the legal right to use the Purchased
Assets and has good title to the Purchased Assets, free and clear of all Liens other than Permitted Encumbrances. 

Section 3.6    Seller Contracts. Since [***], no default or event of default or event, occurrence, condition
or act has occurred, with respect to Seller, or to Seller’s knowledge, with respect to the other contracting Third Party, which, with the giving of notice or the lapse of the time, would become a default or event of default under any Seller
Contract. Since [***], Seller has not received written notice of, the cancellation, modification or termination of any Seller Contract. True, correct and complete copies of all Seller Contracts have been delivered to Buyer. 

Section 3.7    Litigation. [***], there are no (i) outstanding judgments, orders, injunctions or decrees
of any Governmental Authority or arbitration tribunal against it or related to any of the Purchased Assets; (ii) lawsuits, actions or proceedings pending against it with respect to any of the Purchased Assets; or (iii) investigations by
any Governmental Authority, which are pending against it with respect to any of the Purchased Assets. 

Section 3.8    No Debarment. None of the Seller nor its current directors, officers, agents, representatives
or consultants are under investigation by the FDA or other regulatory authorities for debarment action or presently debarred pursuant to the Generic Drug Enforcement Act of 1992, as amended, or any analogous laws. 

Section 3.9    Brokers. No broker, finder or investment banker is entitled to any brokerage, finder’s or
other fee or commission in connection with the transactions contemplated by this Agreement based upon arrangements made by or on behalf of Seller. 

Section 3.10    No Other Representations or Warranties. EXCEPT AS OTHERWISE EXPRESSLY PROVIDED IN THIS ARTICLE
3, THE PURCHASED ASSETS ARE PROVIDED BY SELLER TO BUYER HEREUNDER “AS-IS” AND SELLER MAKES NO OTHER REPRESENTATIONS OR WARRANTIES, EITHER EXPRESS OR IMPLIED, EITHER IN FACT OR BY OPERATION OF LAW, BY
STATUTE, OR OTHERWISE, AND SELLER SPECIFICALLY DISCLAIMS ANY AND ALL IMPLIED OR STATUTORY WARRANTIES WITH RESPECT TO THE PURCHASED ASSETS. WITHOUT LIMITING THE GENERALITY OF THE FOREGOING, THE SELLER MAKES NO REPRESENTATION AND EXTENDS NO WARRANTY
WITH RESPECT TO (A) THE ACCURACY OF ANY INFORMATION CONTAINED IN THE SELLER IND OR THE SELLER DEVELOPMENT AND REGULATORY DOCUMENTATION, (B) THE PROSPECTS OF THE ANTIBODY, 

  
 10 

  

 Confidential Treatment Requested by Vera Therapeutics, Inc. 

Pursuant to 17 C.F.R. § 200.83 
  

 
ANY PRODUCT OR THE PURCHASED ASSETS, OR (C) THE VALIDITY OR ENFORCEABILITY OF, AND NON-INFRINGEMENT WITH RESPECT TO, THE SELLER PATENTS OR THE SELLER
INTELLECTUAL PROPERTY RIGHTS. 
 ARTICLE IV 

REPRESENTATIONS AND WARRANTIES OF BUYER 

Buyer represents and warrants to Seller as follows: 

Section 4.1    Organization and Qualification. Buyer is a corporation duly organized, validly existing and in
good standing under the Laws of the State of Delaware. 
 Section 4.2    Corporate Authorization. Buyer has
all requisite corporate power and authority to execute and deliver this Agreement and to perform its obligations hereunder. The execution and delivery by Buyer of this Agreement and the performance by Buyer of its obligations hereunder have been, or
will have been at the Closing, duly authorized by all requisite corporate action. 
 Section 4.3    Binding
Effect. This Agreement has been duly executed and delivered by Buyer and, assuming the due authorization, execution and delivery by Seller of this Agreement, constitutes a valid and binding obligation of Buyer, enforceable against it in
accordance with its terms, except as enforcement may be limited by bankruptcy, insolvency, reorganization, moratorium or similar laws affecting creditors’ rights generally or by general principles of equity (regardless of whether enforcement is
sought in a proceeding in equity or law). 

Section 4.4    Non-Contravention. The execution, delivery and
performance by Buyer of this Agreement and the consummation of the transactions contemplated hereby do not and will not (i) violate any provision of the certificate of incorporation or bylaws of Buyer; (ii) conflict with, or result in the
breach of, or constitute a default under, any contract, agreement, lease or license to which Buyer is a party, or (iii) assuming compliance with the matters set forth in Section 3.4 and Section 4.5, violate or result in a breach of or
constitute a default under any Law or other restriction of any Governmental Authority to which Buyer is subject; except, with respect to clauses (ii) and (iii), for any violations, breaches, conflicts or defaults, that have not had, and would
not reasonably be expected to have, individually or in the aggregate, a material adverse effect on the ability of Buyer to perform its obligations under this Agreement (a “Buyer Material Adverse Effect”). 

Section 4.5    Governmental Authorization. The execution and delivery by Buyer of this Agreement and the
consummation of the transactions contemplated hereby do not require any consent or approval of any Governmental Authority, except for consents or approvals, the failure of which to obtain has not had, and would not reasonably be expected to have,
individually or in the aggregate, a Buyer Material Adverse Effect. 
 Section 4.6    Hart-Scott-Rodino
Compliance. The Buyer has determined that the transaction contemplated under this Agreement does not require clearance under the Hart-Scott-Rodino Antitrust Improvement Act of 1976, 15 U.S.C. §18a and the regulations promulgated thereunder,
16 C.F.R. §§ 801.1 et seq. 

  
 11 

  

 Confidential Treatment Requested by Vera Therapeutics, Inc. 

Pursuant to 17 C.F.R. § 200.83 
  

 Section 4.7    Financial Capability. Buyer has sufficient
funds to purchase the Purchased Assets and to consummate the transactions and perform its obligations under this Agreement on the terms and subject to the conditions contemplated herein and therein. 

Section 4.8    Brokers. No broker, finder or investment banker is entitled to any brokerage, finder’s or
other fee or commission in connection with the transactions contemplated by this Agreement based upon arrangements made by or on behalf of Buyer. 

Section 4.9    No Inducement or Reliance; Independent Assessment. Buyer and its Affiliates [***]. 

Section 4.10    No Other Representations or Warranties. EXCEPT FOR THE REPRESENTATIONS AND WARRANTIES OF BUYER
EXPRESSLY SET FORTH IN THIS ARTICLE 4, BUYER DOES NOT MAKE ANY REPRESENTATIONS OR WARRANTIES, AND BUYER HEREBY DISCLAIMS ANY OTHER REPRESENTATIONS OR WARRANTIES, WHETHER MADE BY BUYER, OR ANY OF ITS AFFILIATES OR REPRESENTATIVES, WITH RESPECT TO THE
EXECUTION AND DELIVERY OF THIS AGREEMENT TO WHICH IT IS OR WILL BE A PARTY, OR THE TRANSACTIONS CONTEMPLATED HEREBY OR THEREBY, NOTWITHSTANDING THE DELIVERY OR DISCLOSURE TO THE SELLER OR ANY OF ITS REPRESENTATIVES OF ANY DOCUMENTATION OR OTHER
INFORMATION WITH RESPECT TO ANY ONE OR MORE OF THE FOREGOING. 
 ARTICLE V 

COVENANTS 

Section 5.1    Information and Documents. 

(a)    Except for the Purchased Assets, all information received by Buyer and given by or on behalf of the Seller in
connection with this Agreement and the transactions contemplated hereby will be held by Buyer and its Affiliates, agents and representatives as “Confidential Information” of Pfizer, as defined in, and pursuant to the terms of, the
Confidentiality Agreement. From and after the Closing, notwithstanding anything to the contrary in the Confidentiality Agreement, (i) all Purchased Assets shall be deemed, and treated by Seller, its Affiliates, agents and representatives as the
“Confidential Information” (as defined in the Confidentiality Agreement) of Buyer only and (ii) [***] shall be deemed to include information related to the Purchased Assets. 

(b)    From and after the Closing, Seller shall not publish, present, or otherwise disclose, and shall cause its
Affiliates, agents and representatives, and Third Party licensees or contractors, and its and their respective employees and agents and representatives not to disclose any information related to the Antibody, Product or the Purchased Assets, without
the prior written consent of Buyer. For clarity, from and after the Closing, Buyer shall be free to publish, present, or otherwise disclose information related to the Antibody, Product or the Purchased Assets, subject to the Confidentiality
Agreement, if applicable. 

  
 12 

  

 Confidential Treatment Requested by Vera Therapeutics, Inc. 

Pursuant to 17 C.F.R. § 200.83 
  

 (c)    From and after the Closing, upon reasonable advance notice, the
Seller, on the one hand, and Buyer, on the other hand, shall cause to be furnished or to be provided access to the other party and its representatives such financial, Tax and operating data and other available information with respect to the
Purchased Assets, in each case in its then existing form, as such party and its representatives shall from time to time reasonably request in order to complete their legal and regulatory requirements and to complete their Tax returns and for any
other reasonable business purpose, including in respect of litigation (other than litigation between the parties this Agreement or their Affiliates) and insurance matters. Buyer and its Affiliates shall, for a period of [***], keep such materials
reasonably accessible and not destroy or dispose of such materials without the written consent of Seller. Each party shall promptly reimburse the other for such other party’s reasonable out-of-pocket expenses associated with requests made by the requesting party under this Section 5.1, but no other charges shall be payable by the requesting party to the other party in connection with
such requests. In the event either party reasonably determines that any such provision of any such information could be commercially detrimental, violate any Law or contract, or result in the waiver any privilege, the parties shall take all
commercially reasonable measures to permit the compliance with such obligations in a manner that avoids any such harm or consequence. 

Section 5.2    Compliance. Each of the parties hereto agrees to use its commercially reasonable efforts to
consummate and make effective the transactions contemplated by this Agreement, including (i) to comply promptly with all legal requirements that may be imposed on it with respect to this Agreement and the transactions contemplated hereby (which
actions shall include furnishing all information required by applicable Law in connection with approvals of or filings with any Governmental Authority); and (ii) subject to Section 2.2, to obtain any consent, authorization, order or
approval of, or any exemption by, any Governmental Authority or other public or private Third Party required to be obtained or made by Buyer or Seller in connection with the acquisition of the Purchased Assets or the taking of any other action
contemplated by this Agreement. 
 Section 5.3    Transfer of Purchased Assets. Following the Closing,
Seller shall [***], and shall [***]. 
 Section 5.4    Taxes. 

(a)    General. It is understood and agreed between the parties that any payments made under this Agreement are
exclusive of any value added or similar Tax (“VAT”), which shall be added thereon as applicable. In the event any payments made by Buyer to Seller pursuant to this Agreement become subject to withholding Taxes under the Laws of any
jurisdiction, Buyer shall deduct and withhold the amount of such Taxes for the account of Seller to the extent required by applicable Law and such amounts payable to Seller shall be reduced by the amount of Taxes deducted and withheld, which shall
be treated as paid to Seller in accordance with this Agreement. To the extent that Buyer is required to deduct and withhold Taxes on any payments under this Agreement, Buyer shall 

  
 13 

  

 Confidential Treatment Requested by Vera Therapeutics, Inc. 

Pursuant to 17 C.F.R. § 200.83 
  

 
pay the amounts of such Taxes to the proper Governmental Authority in a timely manner and promptly transmit to the payee an official tax certificate or other evidence of such withholding
sufficient to enable Seller to claim such payments of Taxes. Buyer shall provide any Tax forms to Seller that may be reasonably necessary in order for Buyer not to withhold Tax or to withhold Tax at a reduced rate under an applicable bilateral
income Tax treaty. Each party shall provide the other with reasonable assistance to enable the recovery, as permitted by applicable Law, of withholding Taxes, VAT, or similar obligations resulting from payments made under this Agreement, such
recovery to be for the benefit of the party bearing such withholding Tax or VAT. 
 (b)    Tax Actions.
Notwithstanding anything in this Agreement to the contrary, if an action, including but not limited to any assignment of its rights or obligations under this Agreement, or any failure to comply with applicable Laws or filing or record retention
requirements (a “Tax Action”) by a party leads to the imposition of withholding Tax liability or VAT on the other party that would not have been imposed in the absence of a Tax Action or in an increase in such liability above the
liability that would have been imposed in the absence of such Tax Action, then (i) the sum payable by the party that caused the Tax Action (in respect of which such deduction or withholding is required to be made) shall be increased to the
extent necessary to ensure that the other party receives a sum equal to the sum which it would have received had no Tax Action occurred and (ii) the sum payable by the party that caused a Tax Action (in respect of which such deduction or
withholding is required to be made) shall be made to the other party after deduction of the amount required to be so deducted or withheld, which deducted or withheld amount shall be remitted in accordance with applicable Law. For the avoidance of
doubt, a party shall only be liable for increased payments pursuant to this Section 5.4(b) to the extent such party engaged in a Tax Action that created or increased a withholding Tax or VAT on the other party. 

Section 5.5    Cooperation. The parties agree to cooperate and produce on a timely basis any Tax forms or
reports, including an IRS Form W-8BEN, reasonably requested by the other party in connection with any payment made by Buyer to Seller under this Agreement. 

Section 5.6    Pfizer Assurance. [***] For a period of [***] after the Closing Date, [***]. 

ARTICLE VI 

INDEMNIFICATION 

Section 6.1    Indemnification by Seller. 

(a)    Subject to the provisions of this ARTICLE VI, Seller agrees to defend, indemnify and hold harmless Buyer and its
Affiliates, and their respective directors, officers, agents, employees, successors and assigns, from and against any and all claims, actions, causes of action, judgments, awards, Liabilities, losses, costs (including reasonable attorney’s
fees) or damages (collectively, a “Loss” or, the “Losses”) claimed or arising from (i) any Retained Liability, (ii) any breach by Seller of any of its covenants or agreements contained in this Agreement or
(iii) any breach of any representation or 

  
 14 

  

 Confidential Treatment Requested by Vera Therapeutics, Inc. 

Pursuant to 17 C.F.R. § 200.83 
  

 
warranty of Seller contained in this Agreement, except to the extent resulting from (A) any Assumed Liability, (B) any breach by Buyer of any of its covenants or agreements in this
Agreement, or (C) any breach of any representation or warranty of Buyer contained in this Agreement. 

(b)    Buyer acknowledges and agrees that Seller shall not have any Liability under any provision of this Agreement for
any Loss to the extent that such Loss relates to action taken by Buyer or any other Person relating to the Purchased Assets (other than action taken by Seller in breach of this Agreement) on or after the Closing Date. Buyer shall take, and shall
cause its Affiliates to take, all reasonable steps to mitigate any Loss upon becoming aware of any event that would reasonably be expected to, or does, give rise thereto, including incurring costs only to the minimum extent necessary to remedy the
breach that gives rise to the Loss. 
 Section 6.2    Indemnification by Buyer. 

(a)    Subject to the provisions of this ARTICLE VI, Buyer agrees to defend, indemnify and hold harmless Seller and its
Affiliates, and their respective directors, officers, agents, employees, successors and assigns, from and against any and all Loss claimed or arising from (i) any Assumed Liability, (ii) any breach by Buyer of any of its covenants or
agreements in this Agreement, or (iii) any breach of any representation or warranty of Buyer contained in this Agreement, except to the extent resulting from (A) any Retained Liability, (B) any breach by Seller of any of its covenants
or agreements in this Agreement, or (C) any breach of any representation or warranty of Seller contained in this Agreement. 

(b)    Seller shall take, and cause its Affiliates to take, all reasonable steps to mitigate any Loss upon becoming aware
of any event that would reasonably be expected to, or does, give rise thereto, including incurring costs only to the minimum extent necessary to remedy the breach that gives rise to the Loss. 

Section 6.3    Notice of Claims. If any of the Persons to be indemnified under this ARTICLE VI (the
“Indemnified Party”) has suffered or incurred any Loss, the Indemnified Party shall so notify the party from whom indemnification is sought (the “Indemnifying Party”) promptly in writing describing such Loss, the
amount or estimated amount thereof, if known or reasonably capable of estimation, and the method of computation of such Loss, all with reasonable particularity and containing a reference to the provisions of this Agreement or any other agreement or
instrument delivered pursuant hereto in respect of which such Loss shall have occurred. If any action at Law or suit in equity is instituted by or against a Third Party with respect to which the Indemnified Party intends to claim any Liability as a
Loss under this ARTICLE VI, the Indemnified Party shall promptly notify the Indemnifying Party of such action or suit and tender to the Indemnifying Party the defense of such action or suit. A failure by the Indemnified Party to give notice and to
tender the defense of the action or suit in a timely manner pursuant to this Section 6.3 shall not limit the obligation of the Indemnifying Party under this ARTICLE VI, except (i) to the extent such Indemnifying Party is actually
prejudiced thereby, (ii) expenses that are incurred during the period in which notice was not provided shall not be deemed a Loss and (iii) as provided by Section 6.5. 

  
 15 

  

 Confidential Treatment Requested by Vera Therapeutics, Inc. 

Pursuant to 17 C.F.R. § 200.83 
  

 Section 6.4    Third Party Claims. 

(a)    The Indemnifying Party under this ARTICLE VI shall have the right, but not the obligation, to conduct and control,
through counsel of its choosing, the defense of any third party claim, action, suit or proceeding (a “Third Party Claim”). Except with the prior written consent of the Indemnified Party, the Indemnifying Party may compromise or
settle a Third Party Claim that provides for injunctive or other non-monetary relief affecting the Indemnified Party or that does not completely release the Indemnified Party. Should the Indemnifying Party so
elect to conduct and control the defense of any Third Party Claim, the Indemnifying Party shall not be liable to the Indemnified Party for legal expenses subsequently incurred by the Indemnified Party in connection with the defense thereof. No
Indemnified Party may compromise or settle any Third Party Claim for which the Indemnifying Party has assumed the defense hereunder without the consent of the Indemnifying Party. The Indemnifying Party shall permit the Indemnified Party to
participate in, but not control, the defense of any such action or suit through counsel chosen by the Indemnified Party, provided that the fees and expenses of such counsel shall be borne by the Indemnified Party. If the Indemnifying Party
elects not to control or conduct the defense or prosecution of a Third Party Claim, the Indemnified Party shall have the full right to defend against such Third Party Claim and shall be entitled to settle or agree to pay in full such Third Party
Claim and to recover any amounts paid plus all expenses incurred by the Indemnified Party (including attorneys’ fees) from the Indemnifying Party. The Indemnifying Party nevertheless shall have the right to participate in the defense or
prosecution of such Third Party Claim and, at its own expense, to employ counsel of its own choosing for such purpose. 

(b)    The parties hereto shall cooperate in the defense or prosecution of any Third Party Claim, with such cooperation to
include (i) the retention of and the provision to the Indemnifying Party of records and information that are reasonably relevant to such Third Party Claim and (ii) the making available of employees on a mutually convenient basis for
providing additional information and explanation of any material provided hereunder. 

Section 6.5    Expiration. Notwithstanding anything in this Agreement to the contrary except for the next
sentence, if the Closing shall have occurred, all covenants, agreements, representations and warranties made herein shall survive the Closing. Notwithstanding the foregoing, except for a party’s [***], all representations and warranties made
herein, and all indemnification obligations under Section 6.1(a)(iii) and Section 6.2(a)(iii) with respect to any such representation or warranty, shall terminate and expire on, and no action or proceeding seeking damages or other relief
for breach of any thereof or for any misrepresentation or inaccuracy with respect thereto shall be commenced after, [***], unless prior to such [***] a claim for indemnification with respect thereto shall have been made, with reasonable specificity,
by written notice given under Section 6.3. 
 Section 6.6    Losses Net of Insurance, Etc. The amount
of any Loss for which indemnification is provided under Section 6.1 or Section 6.2 shall be net of (i) any amounts recovered by the Indemnified Party pursuant to any indemnification by or indemnification agreement with any Third
Party, or (ii) any insurance proceeds (net of any increase in premiums directly relating to such Loss as reasonably demonstrated by the 

  
 16 

  

 Confidential Treatment Requested by Vera Therapeutics, Inc. 

Pursuant to 17 C.F.R. § 200.83 
  

 
Indemnified Party) or other funds received directly by the Indemnified Party as an offset against such Loss (each Person named in clauses (i) and (ii), a “Collateral
Source”). If the amount to be netted hereunder from any payment required under Section 6.1 or Section 6.2 is determined after payment by the Indemnifying Party of any amount otherwise required to be paid to an Indemnified Party
pursuant to this ARTICLE VI, the Indemnified Party shall repay to the Indemnifying Party, promptly after such determination, any amount that the Indemnifying Party would not have had to pay pursuant to this ARTICLE VI had such determination been
made at the time of such payment. 
 Section 6.7    Sole Remedy. The parties hereto acknowledge and agree
that [***]. 
 Section 6.8    No Consequential Damages. EXCEPT FOR A PARTY’S FRAUDULENT OR WILLFUL
MISCONDUCT, NOTWITHSTANDING ANYTHING TO THE CONTRARY CONTAINED HEREIN, NEITHER PARTY TO THIS AGREEMENT SHALL BE LIABLE TO OR OTHERWISE RESPONSIBLE TO THE OTHER PARTY HERETO OR ANY AFFILIATE OF ANY OTHER PARTY HERETO FOR CONSEQUENTIAL, INCIDENTAL OR
PUNITIVE DAMAGES THAT ARISE OUT OF OR RELATE TO THIS AGREEMENT OR THE PERFORMANCE OR BREACH HEREOF OR ANY LIABILITY RETAINED OR ASSUMED HEREUNDER. THIS SECTION SHALL NOT LIMIT THE DAMAGES RECOVERABLE BY EITHER PARTY IN CONNECTION WITH ANY BREACH OF
THE CONFIDENTIALITY AGREEMENT. 
 ARTICLE VII 

MISCELLANEOUS 

Section 7.1    Notices. All notices or other communications hereunder shall be deemed to have been duly given
and made if in writing and if served by personal delivery upon the party for whom it is intended, if delivered by registered or certified mail, return receipt requested, or by a national courier service, or if sent by facsimile, provided that
the facsimile is promptly confirmed by telephone confirmation thereof, to the Person at the address set forth below, or such other address as may be designated in writing hereafter, in the same manner, by such Person: 

To Seller: 
 Amplyx
Pharmaceuticals, Inc. 
 c/o Pfizer Inc. 

235 East 42nd Street 

New York, NY 10017 
 Attention:
[***] 

  
 17 

  

 Confidential Treatment Requested by Vera Therapeutics, Inc. 

Pursuant to 17 C.F.R. § 200.83 
  

 With a copy to: 

c/o Pfizer Inc. 
 235 East 42nd
Street 
 New York, NY 10017 

Attention: [***] 
 To Buyer: 

Vera Therapeutics, Inc. 
 170
Harbor Way, 3rd Floor 
 South San Francisco, CA 94080 

Attention: [***] 

Section 7.2    Amendment; Waiver. Any provision of this Agreement may be amended or waived if, and only if,
such amendment or waiver is in writing and signed, in the case of an amendment, by Buyer and Seller, or in the case of a waiver, by the party against whom the waiver is to be effective. No failure or delay by any party in exercising any right, power
or privilege hereunder shall operate as a waiver thereof nor shall any single or partial exercise thereof preclude any other or further exercise thereof or the exercise of any other right, power or privilege. 

Section 7.3    Assignment. No party to this Agreement may assign this Agreement, or any of its rights or
obligations under this Agreement, without the prior written consent of the other party hereto, except that either party may, without such consent, assign this Agreement in its entirety to an Affiliates or to a successor in interest in connection
with a merger or sale of all or substantially all of the business or assets to which this Agreement pertains; provided, however, that no such assignment by a Party shall relieve such Party of any of its obligations hereunder, and that
any such assignment by such Party does not adversely affect the other Party or any of its Affiliates. 

Section 7.4    Entire Agreement. This Agreement (including all Schedules and Exhibits), the Assignment and
Assumption Agreement and the Patent Assignment Agreement contain the entire agreement between the parties hereto with respect to the subject matter hereof and supersedes all prior agreements and understandings, oral or written, with respect to such
matters, except for the Confidentiality Agreement which will remain in full force and effect for the term provided for therein and other than any written agreement of the parties that expressly provides that it is not superseded by this Agreement.

 Section 7.5    Fulfillment of Obligations. Any obligation of any party to any other party under this
Agreement, which obligation is performed, satisfied or fulfilled by an Affiliate of such party, shall be deemed to have been performed, satisfied or fulfilled by such party. 

Section 7.6    Parties in Interest. This Agreement shall inure to the benefit of and be binding upon the
parties hereto and their respective successors and permitted assigns. Nothing in this Agreement, express or implied, is intended to confer upon any Person other than Buyer, Seller or their respective successors or permitted assigns, any rights or
remedies under or by reason of this Agreement. 

  
 18 

  

 Confidential Treatment Requested by Vera Therapeutics, Inc. 

Pursuant to 17 C.F.R. § 200.83 
  

 Section 7.7    Public Disclosure. Notwithstanding anything
herein to the contrary, each of the parties to this Agreement hereby agrees with the other parties hereto that, except as may be required to comply with the requirements of any applicable Laws, and the rules and regulations of the SEC or each stock
exchange upon which the securities of either of the parties is listed, no press release or similar public announcement or communication shall, if prior to the Closing, be made or caused to be made concerning the execution or performance of this
Agreement unless the parties shall have consulted in advance with respect thereto. 

Section 7.8    Expenses. Except as otherwise expressly provided in this Agreement, whether or not the
transactions contemplated by this Agreement are consummated, all costs and expenses incurred in connection with this Agreement and the transactions contemplated hereby shall be borne by the party incurring such expenses. For the avoidance of doubt,
Buyer, at their sole cost and expense, shall make all appropriate filings, notices and applications with the applicable Governmental Authority to reflect the sale, transfer and assignment of any Purchased Asset. Notwithstanding the foregoing, all
Taxes (including any value added taxes but excluding any Income Taxes) and fees relating to the transfer of the Purchased Assets shall be paid by Buyer. 

Section 7.9    Governing Law; Jurisdiction. This Agreement shall be governed in all respects, including
validity, interpretation and effect, by the internal laws of the State of New York. The parties hereto agree that the [***] shall have exclusive jurisdiction over any dispute or controversy arising out of or relating to this Agreement and any
judgment, determination, arbitration award, finding or conclusion reached or rendered in any other jurisdiction shall be null and void between the parties hereto. Each party waives any defense of inconvenient forum to the maintenance of any action
or proceeding so brought and waives any bond, surety, or other security that might be required of any other party with respect thereto. 

Section 7.10    Counterparts. This Agreement may be executed in one or more counterparts, each of which shall
be deemed an original, and all of which shall constitute one and the same agreement. 

Section 7.11    Headings. The heading references herein and the table of contents hereto are for convenience
purposes only, do not constitute a part of this Agreement and shall not be deemed to limit or affect any of the provisions hereof. 

Section 7.12    Severability. The provisions of this Agreement shall be deemed severable and the invalidity or
unenforceability of any provision shall not affect the validity or enforceability of the other provisions hereof. If any provision of this Agreement, or the application thereof to any Person or any circumstance, is invalid or unenforceable,
(a) a suitable and equitable provision shall be substituted therefor in order to carry out, so far as may be valid and enforceable, the intent and purpose of such invalid or unenforceable provision and (b) the remainder of this Agreement
and the application of such provision to other Persons or circumstances shall not be affected by such invalidity or unenforceability, nor shall such invalidity or unenforceability affect the validity or enforceability of such provision, or the
application thereof, in any other jurisdiction. 

  
 19 

  

 Confidential Treatment Requested by Vera Therapeutics, Inc. 

Pursuant to 17 C.F.R. § 200.83 
  

 [Remainder of page intentionally blank] 

  
 20 

  

 Confidential Treatment Requested by Vera Therapeutics, Inc. 

Pursuant to 17 C.F.R. § 200.83 
  

 IN WITNESS WHEREOF, the parties have executed or caused this Agreement to be executed as of
the date first written above. 
  

					
	AMPLYX PHARMACEUTICALS, INC.
		
	By:	 	 /s/ Deborah Baron

		 	 Name:
	 	 Deborah Baron

		 	 Title:
	 	 President

	
	VERA THERAPEUTICS, INC.
		
	By:	 	 /s/ Marshall Fordyce

		 	 Name:
	 	 Marshall Fordyce

		 	 Title:
	 	 Chief Executive Officer

 Acknowledged and agreed by Pfizer solely with respect to Section 5.6: 

 

					
	PFIZER INC.
		
	By:	 	 /s/ Deborah Baron

		 	Name:	 	Deborah Baron
		 	Title:	 	SVP Worldwide Business Development

  
 [Signature Page to Asset
Purchase Agreement.] 

  

 Confidential Treatment Requested by Vera Therapeutics, Inc. 

Pursuant to 17 C.F.R. § 200.83 
  

 Exhibit A 

List of instruments and documents to be provided by Seller: [***] 

  

 Confidential Treatment Requested by Vera Therapeutics, Inc. 

Pursuant to 17 C.F.R. § 200.83 
  

 Exhibit B 

List of instruments and documents to be provided by Buyer: [***]EX-10.16

 Confidential Treatment Requested by Vera Therapeutics, Inc. 

Pursuant to 17 C.F.R. § 200.83 
  

 Exhibit 10.16 

Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant
treats as private or confidential. Information that was omitted has been noted in this document with a placeholder identified by the mark “[***]”. 

EXECUTION VERSION 
 LICENSE
AGREEMENT 
 This License Agreement (“Agreement”), made as of August 26, 2019 (“Effective Date”),
is by and between Novartis International Pharmaceutical AG, a corporation organized under the laws of Switzerland, with its principal place of business at Lichtstrasse 35, CH-4056 Basel, Switzerland
(“Novartis”) and Amplyx Pharmaceuticals, Inc., a corporation organized and existing under the laws of Delaware, with a principal place of business at 12730 High Bluff Drive, Suite 160, San Diego, California 92130
(“Company”). Novartis and Company are each referred to individually as a “Party” and together as the “Parties.” 

Background 
 Novartis
Controls (as defined below) the Novartis Patents and the Novartis Know-How (each as defined below) relating to the Antibodies (as defined below). Company is a pharmaceutical company focused on developing
medicines to treat infectious diseases. Company wishes to obtain, and Novartis wishes to grant, rights under the Novartis Technology (as defined below) to develop, make, use and sell Antibodies and Products (as defined below). 

For good and valuable consideration, the Parties agree as follows: 

 

	1.	 DEFINITIONS AND INTERPRETATION 

 

	1.1	 Definitions. Unless the context otherwise requires, the terms in this Agreement with initial letters
capitalized will have the meanings set forth below, or the meaning as designated in the indicated places throughout this Agreement. 

“Accounting Standards” means, with respect to Company, United States Generally Accepted Accounting Principles (US GAAP) and
means, with respect to Novartis, International Financial Reporting Standards (IFRS), in each case, as generally and consistently applied throughout the Party’s organization. Each Party will promptly notify the other Party in the event that it
changes the Accounting Standards pursuant to which its records relating to this Agreement are maintained; provided, however, that each Party may only use internationally recognized accounting principles (e.g., IFRS or US GAAP). 

“Affiliate” means, with respect to a particular Person, any Person that controls, is controlled by, or is under common control
with that Party. For the purpose of this definition, “control” or “controlled” means direct or indirect ownership of [***] or more of the shares of stock entitled to vote for the election of directors, in the case of a
corporation, or [***] or more of the equity interest in the case of any other type of legal entity, status as a general partner in any partnership, or any other arrangement whereby the entity or Person controls or has the

  
 1 

  

 Confidential Treatment Requested by Vera Therapeutics, Inc. 

Pursuant to 17 C.F.R. § 200.83 
  

 
right to control the board of directors or equivalent governing body of a corporation or other entity, or the ability to cause the direction of the management or policies of a corporation or
other entity. In the case of entities organized under the laws of certain countries, the maximum percentage ownership permitted by law for a foreign investor may be less than [***], and in such case such lower percentage will be substituted in the
preceding sentence, provided that such foreign investor has the power to direct the management and policies of such entity. 

“Agreement” has the meaning set forth in the Preamble (i.e., in the first paragraph of this Agreement). 

“Agreement Term” has the meaning set forth in Section 11.1. 

“Alliance Manager” will have the meaning set forth in Section 3.1. 

“Antibody” means (a) the fully human monoclonal antibody referred to as “MAU868” described more fully on
Exhibit A, (b) the monoclonal antibodies claimed in the Patent Rights set forth on Exhibit C, and (c) any [***] 

“Antibody Material” has the meaning set forth in Section 6.1. 

“Applicable Law” means any national, supranational, regional, federal, state, local or foreign law (including common law),
statute or ordinance, or any rule, regulation, judgment, order, writ or decree of or from any court, or other Regulatory Authority or other governmental authority having jurisdiction over or related to the subject item or subject Person that may be
in effect from time to time, including, as applicable, GCP, GLP, and GMP. 
 “Auditor” has the meaning set forth in
Section 8.9(b). 
 “BLA” means a Biologics License Application in the United States for
authorization to market a Product, as defined in the FDC Act and the regulations promulgated thereunder, submitted to the FDA. 

“Biosimilar Product” means, with respect to a Product and on a
country-by-country basis, a product that (a) is marketed for sale in such country by a Third Party (not licensed, supplied or otherwise provided by Company
or its Affiliates or sublicensees); (b) contains the corresponding Product as an active pharmaceutical ingredient or is highly similar to and has no clinically meaningful differences from the corresponding Product; and (c) such
product is approved as a “Biosimilar Biologic Product” under Title VII, Subtitle A Biologics Price Competition and Innovation Act of 2009, Section 42 U.S.C. 262, Section 351 of the PHSA, or, outside the United States, in
accordance with European Directive 2001/83/EC on the Community Code for medicinal products (Article 10(4) and Section 4, Part II of Annex I) and European Regulation EEC/2309/93 establishing the Community procedures for the authorization and
evaluation of medicinal products, each as amended, and together with all associated guidance, and any counterparts thereof or equivalent process inside or outside of the United States or EU to the foregoing. 

  
 2 

  

 Confidential Treatment Requested by Vera Therapeutics, Inc. 

Pursuant to 17 C.F.R. § 200.83 
  

 “Business Day” means a day (other than a Saturday, Sunday or a public
holiday) on which the banks are open for business in Basel, Switzerland, San Diego, California, and Cambridge, Massachusetts. 

“Calendar Quarter” means the respective periods of three consecutive calendar months ending on March 31, June 30,
September 30, and December 31. 
 “Calendar Year” means a period of twelve consecutive calendar months ending on
December 31. 
 “Claims” means all Third Party demands, claims, actions and proceedings and liability (whether criminal
or civil, in contract, tort or otherwise). 
 “CMO” means a contract manufacturing organization. 

“Commercialize” means to market, promote, distribute, import, export, offer to sell or sell a Product, including to conduct
all associated post-launch regulatory activities, including medical affairs oversight, and “Commercialization” means activities to Commercialize a Product. “Commercialize” and “Commercialization” exclude
Manufacture and Manufacturing. 
 “Commercially Reasonable Efforts” means, (a) with respect to the efforts to be
expended by a Party to accomplish any objective (other than any objective relating to Development or Commercialization of an Antibody or Product by a Party, which is covered by clause (b) below), such reasonable, diligent, and good faith
efforts as such Party would normally use to accomplish a similar objective under similar circumstances, and (b) with respect to any objective relating to Development or Commercialization of an Antibody or Product by a Party, the
application by such Party (on its own or acting through any of its Affiliates or sublicensees or subcontractors), consistent with the exercise of prudent scientific and business judgment, of efforts and resources typically used by similarly-sized and similarly-situated biotechnology or pharmaceutical companies, as compared to such Party, to perform the obligation at issue, which efforts will be substantially equivalent to those efforts
commonly made by such Party in an active and ongoing program to Develop and Commercialize a product owned by it or to which it has exclusive rights, which product is of a similar stage of development or in a similar stage of product life as an
Antibody or Product, with similar developmental risk profiles and of similar market and commercial potential as an Antibody or Product, taking into consideration the intellectual property and competitive landscape relevant to such product, the
safety and efficacy profile of a product, anticipated or approved labeling, the regulatory approval (including any reimbursement approval) risks associated with such product, and all other actual or anticipated scientific, technical, commercial and
other relevant factors. “Commercially Reasonable Efforts” shall be determined on a country-by-country and Indication-by-Indication basis for an Antibody or Product, as applicable, and it is anticipated that the level of effort and resources that constitute “Commercially Reasonable Efforts” may change
over time, reflecting changes in the status of an Antibody or Product, as applicable, and the country(ies) involved. 

“Company” has the meaning set forth in the Preamble. 

  
 3 

  

 Confidential Treatment Requested by Vera Therapeutics, Inc. 

Pursuant to 17 C.F.R. § 200.83 
  

 “Company Indemnitees” has the meaning set forth in
Section 14.1. 
 “Confidential Information” means all
Know-How and other information and data provided or made available by or on behalf of a Party to the other Party or any of its Affiliates, during the Agreement Term or previously pursuant to the
confidentiality agreement between the Parties, dated January 24, 2019, whether made available orally, in writing or in electronic form. The terms of this Agreement shall constitute the Confidential Information of both Parties. 

“Control” or “Controlled” means, with respect to any Regulatory Filings, Regulatory Approvals, Know-How, Patent Rights, other intellectual property rights, or any proprietary or trade secret information, the legal authority or right (whether by ownership, license or otherwise, other than by a license granted
under this Agreement) of a Party or its Affiliates, to assign or grant a license or a sublicense of or under or other rights to access and use such Regulatory Filings, Regulatory Approvals, Know-How, Patent
Rights, or intellectual property rights to another Person, or to otherwise disclose or transfer such proprietary or trade secret information to another Person, in each case as provided herein, without breaching the terms of any agreement with a
Third Party or misappropriating the proprietary or trade secret information of a Third Party. 
 “Develop” or
“Development” means all drug or biopharmaceutical development activities, including test method development, assay development and audit development, toxicology, formulation, quality assurance/quality control development,
statistical analysis, clinical studies, packaging development, regulatory affairs, and the preparation, filing, and prosecution of Regulatory Filings as necessary to obtain Regulatory Approval, to market or sell a Product. “Develop” and
“Development” exclude Manufacture and Manufacturing. 
 “Development Plan” has the meaning set forth in
Section 3.2(a). 
 “Development and Commercialization Report” has the meaning set forth in
Section 3.2(b). 
 “Effective Date” has the meaning in the preamble. 

“EMA” means the European Medicines Agency or any successor entity thereto. 

“European Commission” means the authority within the European Union that has the legal authority to grant Regulatory Approvals
in the European Union based on input received from the EMA or other competent Regulatory Authorities. 
 “European Regulatory
Approval” means Regulatory Approval from the EMA or the applicable Regulatory Authority in any of the [***] major European markets [***]. 

“FDA” means the United States Food and Drug Administration or any successor entity thereto. 

“Field” means the diagnosis, prevention, mitigation or treatment of any disease, disorder or condition in humans. 

“FDC Act” has the meaning set forth in Section 13.1(f). 

  
 4 

  

 Confidential Treatment Requested by Vera Therapeutics, Inc. 

Pursuant to 17 C.F.R. § 200.83 
  

 “First Commercial Sale” means, with respect to a Product in a particular
country, the first arm’s length sale to a Third Party for value for use or consumption of any such Product following receipt of Regulatory Approval of such Product in such country. 

“First Patient First Dose” means, with respect to a Product, the administration of the first dose of such Product to the first
patient in the applicable clinical trial. 
 “Force Majeure” has the meaning set forth in
Section 15.6. 
 “GCP” means the then-current ethical, scientific, and quality standards required
by FDA or European Commission for designing, conducting, recording, and reporting trials that involve the participation of human subjects, as set forth in FDA regulations in 21 C.F.R. Parts 11, 50, 54, 56, and 312 and related FDA guidance documents,
and by the International Conference on Harmonization E6: Good Clinical Practices Consolidated Guideline, or as otherwise required by Applicable Laws. 

“GLP” means the then-current good laboratory practice as required by the FDA under 21 C.F.R. part 58 and all applicable FDA
rules, regulations, orders and guidances, and the requirements with respect to current good laboratory practices prescribed by the European Community, the OECD (Organization for Economic Cooperation and Development Council) and the ICH Guidelines,
or as otherwise required by Applicable Laws. 
 “GMP” means the then-current good manufacturing practices and regulations as
required by the FDA under provisions of 21 C.F.R. parts 210 and 211 and all applicable FDA rules, regulations, orders and guidances, and the requirements with respect to current good manufacturing practices prescribed by the European Community under
provisions of “The Rules Governing Medicinal Products in the European Community, Volume 4, Good Manufacturing Practices, Annex 13, Manufacture of Investigational Medicinal Products, July 2003,” or as otherwise required by Applicable Laws.

 “ICC” has the meaning set forth in Section 15.5(b). 

“IND” means any investigational new drug application, clinical trial application or similar application or submission for
approval to conduct human clinical investigations filed with or submitted to a Regulatory Authority in conformance with the requirement of such Regulatory Authority, and any amendments thereto. 

“Indemnification Claim Notice” has the meaning set forth in Section 14.3(b). 

“Indemnified Party” has the meaning set forth in Section 14.3(b). 

“Indemnifying Party” has the meaning set forth in Section 14.3(b). 

“Indication” means a separate defined, well-categorized class of human disease syndrome or medical condition. For clarity,
different stages of the same disease or condition will not be different Indications, different lines of treatment of the same disease or condition will not be different Indications, and the treatment or prevention of the same disease or condition in
different demographic groups (e.g., adult and pediatric) will not be different Indications, but 

  
 5 

  

 Confidential Treatment Requested by Vera Therapeutics, Inc. 

Pursuant to 17 C.F.R. § 200.83 
  

 
treatment of a disease or condition in different patient populations (e.g., renal transplant patients, hematopoietic stem cell transplant patients, and progressive multifocal
leukoencephalopathy patients) will be a different Indication. 
 “Infringement Claim” has the meaning set forth in
Section 9.7. 
 “Insolvency Event” means: 

 

	 	(a)	 Company ceases to function as a going concern by suspending or discontinuing its business;

  

	 	(b)	 Company is the subject of voluntary or involuntary bankruptcy proceedings instituted on behalf of or
against Company (except for involuntary bankruptcy proceedings that are dismissed within [***] days); 

  

	 	(c)	 an administrative receiver, receiver and manager, interim receiver, custodian, sequestrator, or similar
officer is appointed for Company; 

  

	 	(d)	 a resolution to wind up Company is passed at a meeting of the directors or shareholders of Company;

  

	 	(e)	 a resolution is passed by Company or Company’s directors to make an application for an
administration order or to appoint an administrator for all of Company’s assets; or 

  

	 	(f)	 Company makes any general assignment for the benefit of all of its creditors. 

“Invalidity Claim” has the meaning set forth in Section 9.4. 

“Invoice” means an invoice in a form reasonably acceptable to Company and to Novartis. 

“Know-How” means all proprietary or confidential information, know-how and data, trade secrets, specifications, instructions, processes, formulae, materials, expertise and other technology applicable to any
Antibody or Product or to its manufacture, use, research, or development, including, for clarity, all biological, chemical, pharmacological, biochemical, toxicological, pharmaceutical, physical and analytical, safety, quality control, manufacturing,
preclinical and clinical data, instructions, processes, formulae, expertise and information, regulatory filings and copies thereof. 

“Loss of Market Exclusivity” means, with respect to any Product in any country, that a Biosimilar Product has been launched
(i.e., is being sold) in the relevant country by a Third Party. 
 “Losses” means all losses, liabilities, damages,
costs, fees, and expenses (including reasonable attorneys’ fees and litigation expenses). 

  
 6 

  

 Confidential Treatment Requested by Vera Therapeutics, Inc. 

Pursuant to 17 C.F.R. § 200.83 
  

 “MAA” means an application for the authorization to market the Product in
any country or group of countries outside the United States, as defined in the Applicable Laws and filed with the Regulatory Authority of such given country or group of countries. 

“Manufacture” means, with respect to an Antibody or Product, to manufacture, process, formulate, package, label, hold, store,
quality control and release such Antibody or Product, and “Manufacturing” means activities to Manufacture a Product. 

“Manufacturing Know-How” means all Know-How
Controlled by Novartis or any of its Affiliates as of the Effective Date and reasonably necessary or useful to Manufacture Antibodies or Products in the Field. For clarity, Manufacturing Know-How shall exclude
rights under any Manufacturing Patents. 
 “Manufacturing Patents” means the Patent Rights Controlled by Novartis or any of
its Affiliates as of the Effective Date that are reasonably necessary or useful to Manufacture Antibodies or Products in the Field. 

“Manufacturing Technology” means the Manufacturing Patents and the Manufacturing
Know-How. 
 “Manufacturing Technology Improvements” has the meaning set forth in
Section 2.4. 
 “Meeting Hour” means an hour spent by personnel of Novartis or its Affiliates in
direct interaction with personnel of Company or its Affiliates in face-to-face meetings or teleconferences to answer questions or otherwise provide information related
to transferred data and information as contemplated by this Agreement, independent of the number of participants from Novartis or its Affiliates attending the meeting or phone conference, and for time spent in activities responding to Company’s
requests during such meetings, but do not include hours spent by personnel of Novartis or its Affiliates to prepare for the meetings. 

“Milestone” means a milestone relating to a Product, as set forth in Sections 8.3 and 8.4. 

“Milestone Catch-Up Payment” has the meaning set forth in
Section 8.3(d). 
 “Milestone Payment” means the payment to be made by Company to Novartis upon
the achievement of the corresponding Milestone, as set forth in Sections 8.3 and 8.4. 
 “Net Sales” means
[***] 
 “Non-Compete” has the meaning set forth in Section 2.3(a). 

“Novartis” has the meaning set forth in the Preamble. 

“Novartis Indemnitees” has the meaning set forth in Section 14.2. 

“Novartis Know-How” means the Know-How
Controlled by Novartis or any of its Affiliates summarized on Exhibit B. Notwithstanding any other provision of this Agreement, “Novartis Know-How” excludes Manufacturing Know-How. 

  
 7 

  

 Confidential Treatment Requested by Vera Therapeutics, Inc. 

Pursuant to 17 C.F.R. § 200.83 
  

 “Novartis Patents” means the Patent Rights set forth on Exhibit C,
other than any Manufacturing Patents. 
 “Novartis Technology” means the Novartis
Know-How and Novartis Patents. 
 “Party” or “Parties” has the
meaning set forth in the Preamble. 
 “Patent Rights” means: 

 

	 	(a)	 all patent applications, including any provisional patent applications, in any country;

  

	 	(b)	 any patent application claiming priority from such patent application or provisional application,
including all divisionals, continuations, substitutions, continuations-in-part, provisionals, converted provisionals and continued prosecution applications;

  

	 	(c)	 any patent that has issued or in the future issues from any of the foregoing patent applications ((a)
and (b)), including any utility model, petty patent, design patent, and certificate of invention; 

  

	 	(d)	 any re-examinations, reissues, additions, renewals, extensions,
registrations, supplemental protection certificates of any of the foregoing patents or patent applications ((a), (b), and (c)); and 

  

	 	(e)	 any similar rights, including so-called pipeline protection, or
any importation, revalidation, confirmation or introduction patent or registration patent or patent of additions to any such foregoing patent application or patent. 

“Person” means any individual, partnership, limited liability company, firm, corporation, association, trust, unincorporated
organization or other entity. 
 “Pharmacovigilance Agreement(s)” has the meaning set forth in
Section 5.2. 
 “Phase II Clinical Trial” means a clinical study of an investigational product in
humans with the primary objective of characterizing its activity in a specific disease state as well as generating more detailed safety, tolerability, and pharmacokinetics information, as described in U.S. 21 C.F.R. Part 312.21(b), or a comparable
clinical study prescribed by the relevant Regulatory Authority in a country other than the United States, including a human clinical trial that is also designed to satisfy the requirements of 21 C.F.R. 312.12(a) or corresponding foreign regulations
and is subsequently optimized or expanded to satisfy the requirements of 21 C.F.R. 312.12(b) or corresponding foreign regulations, or otherwise to enable a Phase III Clinical Trial (e.g., a phase I/II clinical trial). 

“Phase III Clinical Trial” means a controlled clinical study of an investigational product in patients that incorporates
accepted endpoints for confirmation of statistical significance of efficacy and safety with the aim to obtain Regulatory Approval, as described in 21 C.F.R. 312.21(c), or a comparable clinical study prescribed by the relevant Regulatory Authority in
a country other than the United States. 

  
 8 

  

 Confidential Treatment Requested by Vera Therapeutics, Inc. 

Pursuant to 17 C.F.R. § 200.83 
  

 “PRC” means the People’s Republic of China, including the Hong Kong
Special Administrative Region, the Macau Special Administrative Region, and Taiwan. 
 “Pricing Reimbursement Approval”
means the authorization or approval of pricing or reimbursement for a pharmaceutical product in a country or jurisdiction by the relevant Regulatory Authority, government agency, or other body responsible for such activities in such jurisdiction(s)
under Applicable Law. 
 “Product” means any product in any dosage strength or formulation containing, incorporating or
comprising an Antibody, either alone or in combination with other agents. 
 “Product Marks” has the meaning set forth in
Section 9.7. 
 “Regulatory Approval” means, with respect to a Product in any country or
jurisdiction, any approval, registration, license or authorization from a Regulatory Authority in such country or other jurisdiction that is necessary to market and sell a Product in such country or jurisdiction, and includes Pricing Reimbursement
Approval only if legally required for sale to a Third Party for use or consumption of such Product in such country. For clarity, approval by the applicable Regulatory Authority of a BLA for a Product in the United States or an MAA for a Product in
any other country or jurisdiction shall constitute Regulatory Approval of such Product in such country or jurisdiction. 

“Regulatory Authority” means any governmental authority or agency responsible for authorizing or approving the marketing or
sale of pharmaceutical products in a jurisdiction (e.g., the FDA, European Commission or EMA, the Japanese Ministry of Health, Labour and Welfare, and corresponding national or regional regulatory agencies or organizations). 

“Regulatory Exclusivity” means the ability to exclude Third Parties from marketing and selling a Product in a country, whether
through data exclusivity rights, orphan drug designation, or such other rights conferred by a Regulatory Authority in such country, other than through Patent Rights. 

“Regulatory Filings” means, with respect to an Antibody or Product, any submission to a Regulatory Authority of any
appropriate regulatory application, including any IND, BLA, MAA, or the corresponding application in any other country or group of countries, and any supplement or amendment thereto. 

“Royalty Term” means, on a Product-by-Product
and country-by-country basis, the period commencing on the First Commercial Sale of such Product in such country until the latest of: 

[***] 

“Sales & Royalty Report” means a written report or reports showing each of: 

 

	 	(a)	 the Net Sales of each Product, on a country-by-country basis, during the reporting period by Company and its
Affiliates and sublicensees (for the purpose of this definition, “sublicensees” will not include any distributors or wholesalers), the amount of any adjustments to royalties payable in accordance with Section 8.6; and

  
 9 

  

 Confidential Treatment Requested by Vera Therapeutics, Inc. 

Pursuant to 17 C.F.R. § 200.83 
  

	 	(b)	 the resulting total royalties payable, in USD, which will have accrued hereunder with respect to such
Net Sales. 

 “SEC” means the United States Securities and Exchange Commission, or any successor agency
thereto. 
 “Senior Officers” means, [***] 

“Stock Issuance Agreement” means the Series C-1 Preferred Stock Issuance Agreement,
dated as of the Effective Date, by and between Company and Novartis Institutes for BioMedical Research, Inc. 
 “Specified Primary
Endpoint” means the primary endpoint, as defined in the clinical trial protocol for a multiple-dose Phase II Clinical Trial of a Product for a specified Indication. 

“Sublicense Consideration” has the meaning set forth in Section 8.7(a). 

“Sublicense Percentage” means (a) with respect to a sublicense first granted prior to the First Patient First Dose
of any Product in a Phase III Clinical Trial, [***], and (b) with respect to a sublicense first granted after the First Patient First Dose of any Product in a Phase III Clinical Trial, [***]. 

“Tax” or “Taxes” means any form of tax or taxation, levy, duty, charge, social security charge, contribution,
or withholding in the nature of a tax (including any related fine, penalty, surcharge or interest) imposed by, or payable to, a governmental authority. 

“Terminated Product” means the Product or Antibody that is affected by the termination of the Agreement, in its entirety or on
a Product-by-Product or country-by-country basis. In the case of termination of this
Agreement in its entirety, all Products shall be deemed Terminated Products. 
 “Terminated Territory” means, with respect
to a Terminated Product, those countries for which this Agreement has been terminated and, in the case of termination of this Agreement in its entirety, all countries of the world. 

“Termination Date” has the meaning set forth in Section 12.1(a). 

“Territory” means worldwide. 

“Third Party” means any Person other than a Party or an Affiliate of a Party. 

“Third Party Acquisition” means an acquisition by Novartis or its Affiliate of a Third Party or a portion of the business of a
Third Party (whether by merger or acquisition of all or substantially all of the stock or all or substantially all of the assets of such Third Party or of any operating or business division of such Third Party or similar transaction). 

“Third Party Infringement” has the meaning set forth in Section 9.3(a). 

  
 10 

  

 Confidential Treatment Requested by Vera Therapeutics, Inc. 

Pursuant to 17 C.F.R. § 200.83 
  

 “United States” or “US” means the United States of America,
its territories and possessions. 
 “USD” means US Dollars. 

“Valid Claim” means 
  

	 	(a)	 claim of an issued and unexpired patent included within the Novartis Patents that:

  

	 	(i)	 has not been irrevocably or unappealably disclaimed or abandoned, or been held unenforceable,
unpatentable or invalid by a decision of a court or other governmental agency of competent jurisdiction; and 

  

	 	(ii)	 has not been admitted to be invalid or unenforceable through reissue,
re-examination, disclaimer, or otherwise; or 

  

	 	(b)	 a claim included in a patent application included within the Novartis Patents that has not been
cancelled, withdrawn or abandoned, nor been pending for more than seven years from the earliest filing date to which such patent application or claim is entitled. 

 

	1.2	 Interpretation. In this agreement unless otherwise specified: 

 

	 	(a)	 “includes” and “including” will mean, respectively, includes and including without
limitation; 

  

	 	(b)	 a Party includes its permitted successors and assignees; 

 

	 	(c)	 a statute or statutory instrument or any of their provisions is to be construed as a reference to that
statute or statutory instrument or such provision as the same may have been or may from time to time hereafter be amended or re-enacted; 

 

	 	(d)	 words denoting the singular will include the plural and vice versa and words denoting any gender will
include all genders; 

  

	 	(e)	 the Exhibits and other attachments form part of the operative provision of this Agreement and references
to this Agreement shall, unless the context otherwise requires, include references to the Exhibits and attachments; 

  

	 	(f)	 the headings in this Agreement are for information only and will not be considered in the interpretation
of this Agreement; 

  

	 	(g)	 general words will not be given a restrictive interpretation by reason of their being preceded or
followed by words indicating a particular class of acts, matters or things; 

  

	 	(h)	 references to “days” will mean calendar days unless otherwise indicated;

  

	 	(i)	 the word “or” shall mean “and/or” unless the context otherwise requires; and

  
 11 

  

 Confidential Treatment Requested by Vera Therapeutics, Inc. 

Pursuant to 17 C.F.R. § 200.83 
  

	 	(j)	 the terms and conditions of this Agreement are the result of negotiations between the Parties and that
this Agreement will not be construed in favor of or against any Party by reason of the extent to which any Party participated in the preparation of this Agreement. 

 

	2.	 LICENSES 

  

	2.1	 License Grant. 

 

	 	(a)	 Subject to the terms and conditions of this Agreement, Novartis hereby grants to Company a sublicensable
(in accordance with Section 2.2) license under the Novartis Technology to research, Develop, make, have made, use, import, sell, offer for sale and otherwise Commercialize the Antibodies and Products in the Field in the Territory.
Subject to the retained rights set forth in Section 2.3, the license set forth in this Section 2.1 shall be exclusive (even as to Novartis and its Affiliates). 

 

	 	(b)	 Subject to the terms and conditions of this Agreement, including Sections 2.2 and 6.4(b),
Novartis hereby grants to Company a non-exclusive, sublicensable (in accordance with Section 2.2) license under the Manufacturing Technology to use and practice the Manufacturing Technology in the
Territory solely to have Manufactured by CMOs (pursuant to the conditions of such Manufacturing contained in this Agreement, including Section 6.4) the Antibodies and Products for the research, Development, use, import,
sale, offer for sale, and other Commercialization of the Antibodies and the Products in the Field in the Territory. 

  

	2.2	 Sublicense Rights. Subject to Section 8.7, Company may sublicense (through multiple tiers)
the license set forth in Section 2.1, subject to the applicable terms of this Agreement; provided, that in no event shall Company or any sublicensee sublicense the Manufacturing Technology to any Person, including any academic
institution, other than a CMO as contemplated by Section 6.4(b). Company shall provide Novartis with a copy of any such sublicense agreement within [***] after the execution thereof, provided that such copy may be subject to
redaction as reasonably appropriate to protect sensitive financial provisions, but only to the extent such provisions are not necessary to confirm compliance with this Agreement. Each sublicense of the Novartis Technology and Manufacturing
Technology shall be consistent with the terms and conditions of this Agreement, and Company will remain liable for the performance or failure to perform of its sublicensees and Affiliates under their respective sublicensed rights to the same extent
as if such activity were performed (or was failed to be performed) by Company. Each sublicense shall obligate the sublicensee thereunder to comply with all applicable terms of this Agreement, including this Section 2.2 and Sections
8.7, 8.9 and 10. 

  

	2.3	 Retained Rights. 

 

	 	(a)	 Notwithstanding anything to the contrary in this Agreement, Novartis, its Affiliates, and its and their
agents will retain the right to use the Novartis Technology (i) in order to perform its obligations under this Agreement, and (ii) for purposes of research and development by or on behalf of Novartis or its Affiliates;
provided that, for a period of [***] after the Effective Date, Novartis shall not, whether by itself or through an 

  
 12 

  

 Confidential Treatment Requested by Vera Therapeutics, Inc. 

Pursuant to 17 C.F.R. § 200.83 
  

	 	
Affiliate or Third Party, and shall not enable or facilitate any Affiliate or Third Party to, research, develop, make, have made, use, import, sell, offer for sale or otherwise promote any
product containing, incorporating or comprising any monoclonal antibody intended to target BK virus protein VP1 and therapeutically treat BK virus disease, other than (A) any such product acquired by Novartis or its Affiliate as a result of a Third
Party Acquisition or (B) any such product technically developed or manufactured at arms’ length for a Third Party in accordance with a fee-for-services contract manufacturing services agreement between such Third Party and Novartis or its
Affiliate(the “Non-Compete”). As used herein, “monoclonal antibody” means an intact antibody and antigen-binding antibody fragments thereof, including single chain fragments, monovalent fragments and single domain
fragments, and including bivalent, multispecific, human, humanized, non-human, and chimeric versions of any of the foregoing. 

 

	 	(b)	 Notwithstanding anything to the contrary in this Agreement, Novartis and its Affiliates retain the right
to use for any purpose any learning, skills, ideas, concepts, techniques, know-how and information, including general methodologies and general SAR (structure-activity relationship) concepts, retained in
intangible form in the unaided memory of Novartis’s (or its Affiliate’s) directors, employees, contractors, advisors, agents and other personnel of Novartis (or its Affiliates) who had access to the Novartis Technology or Manufacturing
Technology; provided that Novartis complies with the Non-Compete and Article 10. 

  

	 	(c)	 Without prejudice to any other rights that Novartis may have, and without limiting the license set forth
in Section 2.1, the Non-Compete, and Company’s rights under Sections 2.2, 4.1(b), 4.1(d), and 4.2(b), Company acknowledges and agrees that, as between the Parties, Novartis retains full and unencumbered
rights under the Manufacturing Technology. Company further acknowledges and agrees that, as between the Parties, Novartis or its Affiliates are the sole owner(s) of all right, title and interest in and to the Manufacturing Technology, and Company
has not acquired, and shall not acquire, any right, title or interest in or to the Manufacturing Technology, other than the non-exclusive license expressly set forth in this Agreement. 

 

	2.4	 Grant Back. If Company or any Affiliate or sublicensee thereof, either itself or through or in
collaboration with any Third Party, to the extent permitted under the conditions of this Agreement, further develops or evolves improvements to the Manufacturing Technology, (a) Company automatically and without further action hereunder hereby
grants to Novartis a non-exclusive, royalty free, sublicensable, worldwide license to any such improvements to Manufacturing Technology Controlled by Company, provided that, any such improvements (collectively, “Manufacturing
Technology Improvements”) shall not include any cell line or Manufacturing process developed or generated by or on behalf of Company or any Affiliate or sublicensee thereof without use of or access to the Manufacturing Technology, and in
the event any such Third Party is a CMO, Company shall use Commercially Reasonable Efforts to obtain an assignment or license of any such improvements to Manufacturing Technology developed or generated by on or behalf of such CMO, and
(b) Company shall not at any time during the Agreement Term seek any Patent Rights with respect to such Manufacturing Technology Improvements. 

  
 13 

  

 Confidential Treatment Requested by Vera Therapeutics, Inc. 

Pursuant to 17 C.F.R. § 200.83 
  

	2.5	 Know-How Unrelated to Antibodies or Products. Company
acknowledges that some of the Novartis Know-How disclosed to Company under this Agreement may include documents or materials that include information, data or other Know-How which is unrelated to the Antibodies or Products, and Novartis will use
Commercially Reasonable Efforts to redact or delete such information, data or other Know-How prior to disclosure to Company or to otherwise exclude portions of such documents or materials from disclosure to
the extent such portions are unrelated to the Antibodies and Products. Notwithstanding such efforts, to the extent that such information, data or other Know-How is disclosed to Company or its Affiliates, no
license is granted to Company to use such information, data or Know-How for any purpose or to disclose such information, data or Know-How to any Person, and such
information, data and Know-How shall be deemed to be Novartis’ Confidential Information and not subject to disclosure or use by Company or its Affiliates, pursuant to Section 10.3(c) or
otherwise. 

  

	3.	 GOVERNANCE; INFORMATION UPDATES 

 

	3.1	 Alliance Managers. Within [***] after the Effective Date, each Party will appoint (and notify the
other Party of the identity of) a senior representative having a general understanding of pharmaceutical development and commercialization issues to act as its alliance manager under this Agreement (“Alliance Manager”). The Alliance
Managers will (a) serve as the contact point between the Parties for the purpose of providing Novartis with information on the progress of the Development, Manufacture, and Commercialization of Antibodies and Products by or on behalf
of Company; (b) be primarily responsible for facilitating the flow of information and otherwise promoting communication, coordination, and collaboration between the Parties, including in particular in connection with the
disclosure of Know-How from Novartis to Company as described in Section 4; (c) provide a single point of communication for seeking consensus both internally within the respective Party’s organization and
facilitating review of external corporate communications; and (d) raise cross-Party or cross-functional disputes in a timely manner. Each Party may replace its Alliance Manager on written notice to the other Party.

  

	3.2	 Development Plans; Reports. 

 

	 	(a)	 Within [***] after the Effective Date, Company will provide Novartis with a summary development plan
setting forth the anticipated Development activities to be conducted by or on behalf of Company related to the Antibodies and Products during the following [***] period (the “Development Plan”). No later than [***] Company will
update the Development Plan and provide a summary, in reasonable detail, of the anticipated Development activities to be conducted by or on behalf of Company during the following [***] period. 

 

	 	(b)	 Within [***] Company will provide to Novartis a written summary of all Development and, if applicable,
Commercialization activities that Company, its Affiliates, or their respective agents or sublicensees have conducted in [***] (each, a “Development and Commercialization Report”). The Development and Commercialization Report will
include sufficient information to reasonably determine if Company is in compliance with its obligations under Section 5.1(c) and Section 7.2 of this Agreement. If

  
 14 

  

 Confidential Treatment Requested by Vera Therapeutics, Inc. 

Pursuant to 17 C.F.R. § 200.83 
  

	 	
Manufacturing of any Antibody or Product is based on Manufacturing Technology licensed hereunder, the Development and Commercialization Report shall also include the activities related to
Manufacturing of Antibodies or Products and potential or actual Manufacturing Technology Improvements. 

  

	3.3	 Meetings. Upon Novartis’s request [***] the Alliance Managers will meet (either in person or by
teleconference) to review the Development Plan and Development and Commercialization Report and to discuss Company’s Development and Commercialization activities and activities related to Manufacturing Technology. 

 

	4.	 DISCLOSURE OF LICENSOR KNOW-HOW & COOPERATION

  

	4.1	 Know-How Delivery. 

 

	 	(a)	 Except with respect to documentation related to Manufacturing Technology, Novartis shall provide to
Company an electronic copy of the documentation listed in Exhibit B-1 (including the safety information identified therein) within [***] If any such documentation is not available in electronic format,
Novartis shall use its Commercially Reasonable Efforts to provide a hard copy of such documentation within [***]. The Parties acknowledge that the disclosure by Novartis of such Know-How will consist of the
disclosure of data residing in Novartis’ databases, and will not include any database architecture or require any experimental work performed by Novartis for the purpose of technology transfer. 

 

	 	(b)	 Company acknowledges that Novartis will disclose to Company information related to Manufacturing
Technology in a staggered manner and solely on an as-needed basis. To facilitate the obtaining or maintaining of any Regulatory Approvals for Products by Company, Novartis will, as required in connection with
a Regulatory Filing, and to the extent not contained within any Regulatory Filing transferred to Company pursuant to Section 4.1(a), timely (i) provide qualitative composition of cell culture media directly to Company,
provided that Company acknowledges and agrees that it may use such information solely for purposes of the applicable Regulatory Filing, and (ii) elect in its sole discretion to either (A) provide quantitative composition of cell culture
media directly to the applicable Regulatory Authority, or (B) provide Company with a right of reference to an appropriate Regulatory Filing covering the Manufacturing Technology, including the cell culture media. Company acknowledges that this
is a material provision of this Agreement. 

  

	 	(c)	 Except with respect to data or information related to Manufacturing Technology, during [***], if Company
or Novartis identifies other information or data in Novartis’ Control as of Effective Date and that is reasonably necessary for the continued Development of the Antibodies or Products, Novartis will use Commercially Reasonable Efforts to
provide such information or data to the extent it remains within Novartis’s possession or Control at the time of such identification, and such other information shall be deemed to be Novartis Know-How and
licensed for Company’s use under this Agreement, subject to Section 2.4. 

  
 15 

  

 Confidential Treatment Requested by Vera Therapeutics, Inc. 

Pursuant to 17 C.F.R. § 200.83 
  

	 	(d)	 Copies of Regulatory Filings, the most recent draft of documents prepared for Regulatory Filing,
Regulatory Approvals (if any) and Pricing Reimbursement Approvals (if any), and all written correspondence with Regulatory Authorities, in each case, solely to the extent related to any Antibody or Product, that Novartis or its Affiliates Control as
of the Effective Date, are identified in Exhibit F and will be transferred to Company as set forth in Sections 4.1(a)-(c); provided, that Novartis, as of the Effective Date, hereby assigns all of its rights, title and interests in and
to any and all INDs filed with the FDA covering any Antibody or Product, and, within [***], Novartis will notify the FDA of the transfer of all such INDs to Company pursuant to a form of notice reasonably acceptable to Company, provided,
further, that if Novartis is restricted under Applicable Law from transferring any of the foregoing items to Company, Novartis shall grant, and hereby does grant, to Company a right of reference or use to such item. At the request of Company,
Novartis shall promptly take all permitted actions reasonably necessary to effect such transfer or grant of right of reference or use to Company. 

  

	4.2	 Know-How Transfer Assistance. 

 

	 	(a)	 Except with respect to Manufacturing Technology, [***] and upon Company’s reasonable request,
Novartis shall use Commercially Reasonable Efforts to answer questions regarding the Know-How provided to Company pursuant to Section 4.1, at no additional cost to Company. Such assistance shall be limited to interpretation for
explanation of the Novartis Know-How that is provided to Company under Section 4.1, and in no event shall Novartis be required to provide further strategic guidance, analysis, or other consulting services relating to Company’s
efforts to research, Develop or Commercialize the Antibodies or Products. Novartis shall provide such assistance solely to Company or its Affiliates, and not to any Third Party (e.g., service providers or contract manufacturers of Company).
The Parties’ Alliance Managers will agree on the format, timing, and scope of the relevant Know-How assistance; provided that [***]. 

  

	 	(b)	 For CMC-related transfer activities, as set forth in Exhibit B-2, the total amount of transfer assistance provided by Novartis shall not [***] Notwithstanding the foregoing, disclosure of the quantitative composition of the cell culture media as contemplated by
Section 4.1(b) shall not be subject to the foregoing limitations, and shall take place when reasonably requested by Company in connection with regulatory submissions. 

 

	 	(c)	 If Company requests additional assistance of the type provided for in Section 4.2(a) [***],
Novartis will in good faith consider providing such assistance but will be under no obligation to do so. Any such additional assistance will be limited to [***] and shall be provided pursuant to a written task order describing the scope of the
agreed upon assistance, and Novartis will charge Company at the rate of [***] per FTE for such services. 

  
 16 

  

 Confidential Treatment Requested by Vera Therapeutics, Inc. 

Pursuant to 17 C.F.R. § 200.83 
  

	 	(d)	 To the extent that the services described in Section 4.2(a) and 4.2(b) require
Novartis to engage a Third Party service provider, the costs of such Third Party will be paid exclusively by Company. 

  

	 	(e)	 For clarity, except as expressly set forth herein and as otherwise agreed to by the Parties, all
assistance pursuant to this Section 4.2 will be provided remotely (e.g., e-mail, telephone or video conferences) and shall not require travel by Novartis personnel. 

 

	4.3	 Acknowledgment Regarding Personnel. Company acknowledges that many of the scientists and other
key personnel who have been involved in the research and Development of Antibodies and Products are no longer employed or engaged by Novartis or its Affiliates as of the Effective Date. Nothing contained herein, express or implied, shall require
Novartis to seek information or assistance from any such scientists or other key personnel in order to perform its obligations under this Agreement and, with respect to scientists and other key personnel who are employed or engaged by Novartis or
its Affiliates as of the Effective Date, nothing shall preclude the right of Novartis or its Affiliates to terminate the employment or engagement of any employee or independent contractor at any time and for any reason. 

 

	4.4	 Disclaimer of Warranties. Company acknowledges that all of the Know-How provided to Company pursuant to Section 4.1 and any assistance provided pursuant to Section 4.2 is provided “as is” and
“where is,” without representation or warranty of any kind, except as expressly set forth in Section 13. Novartis hereby expressly disclaims any and all other warranties with respect to such Know-How and assistance, including implied warranties of merchantability or fitness for a particular purpose. Novartis will have no obligation to update, revise, amend, or modify any of the Know-How or assistance provided to Company pursuant to this Section 4 or otherwise in this Agreement, including with respect to documents that are in “draft” or
“incomplete” form as of the Effective Date. For clarity, in no event will Novartis be required to conduct additional experiments or research in connection with its activities described in this Section 4.

  

	4.5	 Third Party Vendors and Service Providers. The Parties acknowledge that Novartis
and its Affiliates will not transfer or assign any agreements that it or they may have with vendors or service providers (e.g., contract research organizations, contract clinical trial sites, consultants, etc.) in connection with
the transactions contemplated by this Agreement. To the extent that Company proposes to engage one or more of such vendors and service providers in connection with the Development or Commercialization of an Antibody or Product after the
Effective Date, at Company’s written request, Novartis will provide reasonable assistance to Company in such efforts by issuing a letter of authorization to enable Company to request access to or copies of any information or documents
identified in Exhibit B from any such vendor or service provider, solely to the extent related to the applicable Antibody or Product held by such vendors or service providers, at Company’s sole cost and expense and pursuant to a separate
agreement to be entered into between Company and any such vendors or service providers. 

  
 17 

  

 Confidential Treatment Requested by Vera Therapeutics, Inc. 

Pursuant to 17 C.F.R. § 200.83 
  

	5.	 DEVELOPMENT; REGULATORY 

 

	5.1	 Development and Regulatory Obligations. 

 

	 	(a)	 Following the Effective Date, Company will be solely responsible for all research and Development of
Antibodies and Products, including all regulatory matters arising in connection therewith, at its own cost and expense. 

  

	 	(b)	 Company shall notify Novartis in writing of each material Regulatory Filing submitted to a Regulatory
Authority by Company, its Affiliates or sublicensees that is based upon, incorporates, or references Manufacturing Technology within [***] If the applicable Regulatory Authority raises any issue or question related to Manufacturing Technology,
whether or not as applicable for an Antibody or Product, Company shall notify Novartis [***] including providing a copy of any related correspondence and other documentation, shall consult with Novartis with respect to its response, and shall
incorporate Novartis’s reasonable comments related to the Manufacturing Technology prior to responding to such Regulatory Authority. Novartis shall provide timely, reasonable assistance to Company in responding to such issues or questions from
Regulatory Authorities relating to the Manufacturing Technology. For clarity, if Novartis elected to provide the quantitative composition of the cell culture media directly to the Regulatory Authority under Section 4.1(b) and the Regulatory
Authority has questions or issues concerning the quantitative composition of the cell culture media, Novartis may elect to respond directly to the Regulatory Authority, and is not required to provide a copy of such response to Company.

  

	 	(c)	 Company will itself, or through its Affiliates or sublicensees, use Commercially Reasonable Efforts to Develop
and obtain [***] 

  

	5.2	 Pharmacovigilance. Company and Novartis shall cooperate with regard to the reporting and handling of
safety information involving or relating to the Antibodies or the Products to the extent required by Applicable Laws. In time to ensure that all regulatory requirements are met, and to the extent required by Applicable Laws or any Regulatory
Authority, Company will enter into written agreement(s) with Novartis and its Affiliates containing customary terms that will govern the exchange of adverse event and other safety information reporting obligations relating to the Antibodies or the
Products (the “Pharmacovigilance Agreement(s)”), to ensure that adverse events and other safety information is exchanged and reported to the relevant Regulatory Authorities in compliance with the Applicable Laws and requirements of
Regulatory Authorities.  

  

	6.	 MATERIAL TRANSFER; MANUFACTURING. 

 

	6.1	 Transfer of Antibody Material. As soon as reasonably practicable after the Effective Date, and in
any event [***] Novartis will use its Commercially Reasonable Efforts to make available for pick-up (either free carrier or ex works, Incoterms 2010, at Novartis’ discretion) the material identified on Exhibit D (the “Antibody
Material”), in the form as such material currently exists, from Novartis’, its Affiliates’, or any Third Party’s facilities where such Antibody Material is currently stored, at no additional cost to Company. [***]

  
 18 

  

 Confidential Treatment Requested by Vera Therapeutics, Inc. 

Pursuant to 17 C.F.R. § 200.83 
  

	6.2	 Disclaimer; Restrictions on Use. Except as expressly set forth in Section 13.5, any Antibody
Material transferred to Company pursuant to this Agreement is provided “as is” and “where is”, and without representation or warranty of any kind, and Novartis hereby expressly disclaims any and all other warranties with respect
to such Antibody Material, including any implied warranties of merchantability and fitness for a particular purpose. 

  

	6.3	 Documentation and Transfer Process. In connection with the transfer of the Antibody Material as
described in Section 6.1, the following shall apply: 

  

	 	(a)	 Novartis will share with Company any MSDSs and customs value information to the extent
(i) readily available to Novartis (and not otherwise available to Company), and (ii) reasonably necessary to permit Company to pick up the Antibody Material in accordance with Applicable Law and this Agreement;

  

	 	(b)	 Company will be solely responsible for any re-testing associated
with the Antibody Material prior to use; 

  

	 	(c)	 with respect to any released Antibody Material, Novartis will provide the certificate of analysis
associated with its release; 

  

	 	(d)	 Company will be responsible for all documentation, licenses, customs clearance, costs, etc. that
are needed for and related to the pick-up, transport, and subsequent delivery of the Antibody Material to the first destination as designated by Company and thereafter; 

 

	 	(e)	 unless Novartis otherwise agrees in writing, the Antibody Material will not be picked up from any one
location in more than one installment; and 

  

	 	(f)	 the Antibody Material made available by Novartis will only be used according to its specifications,
including release specifications, and in accordance with Applicable Laws, and Novartis will have no further obligation with respect to the Antibody Material. 

 

	6.4	 Manufacturing Technology. 

 

	 	(a)	 Limited Rights. Company acknowledges that the process for Manufacturing Antibodies is based upon the
Manufacturing Technology, all of which is proprietary to Novartis. Company further acknowledges that it does not and will not receive any rights in or to the Manufacturing Technology other than the
non-exclusive license solely for the purpose to Develop and Commercialize Antibody as set forth in Section 2.1(b). Company acknowledges that this is a material provision of this
Agreement. 

  

	 	(b)	 CMOs. Notwithstanding the provisions of Section 2.2 of this Agreement, Company
shall establish processes related to the cell bank and drug substance processes as part of the Manufacturing Technology solely at a CMO. Company is recommended, but not required, to use [***] In the event that Company elects to use a CMO other than
the aforementioned, Company shall be prohibited from establishing or transferring the Manufacturing Technology to any such CMO or geographical site except with the 

  
 19 

  

 Confidential Treatment Requested by Vera Therapeutics, Inc. 

Pursuant to 17 C.F.R. § 200.83 
  

	 	
specific prior written approval of Novartis, in its sole discretion. Any contract with a CMO shall highlight the confidential nature of the Manufacturing Technology and the Antibody. If Company
wishes to develop or generate its own cell line that does not use any Manufacturing Technology, Company may do so and may then use a CMO for its own cell line without requiring the prior consent of Novartis. 

 

	 	(c)	 Technical Development. Company acknowledges that Novartis is providing the Manufacturing Technology to
Company “as is” and that Novartis will not perform additional development, testing or Manufacturing. Company is solely responsible for the buildup of its own supply chain. Upon notice by Company of its selection of a CMO, and specific
prior approval of Novartis of such CMO if required under Section 6.4(b), Novartis will support Company in its efforts to establish CMOs for technical development and manufacturing in a paper-based manner and within a time
frame of [***] For the sake of clarity, Novartis will not provide consulting to Company in respect of further Development, Commercialization or Regulatory Approvals, except as set forth in Section 4.2.

  

	 	(d)	 Cell Bank. Novartis will provide a portion of the project-specific cell bank to Company’s CMO
selected in accordance with Section 6.4(b) as provided in Exhibit E; provided, that Company shall not transfer any portion of the project-specific cell bank provided to Company by Novartis to any Third Party
other than a CMO permitted as provided under Section 6.4(b) and shall not, directly or indirectly, itself or through any Affiliate or sublicensee reverse engineer any portion of the project-specific cell bank provided to
Company by Novartis. Generation of additional cell banks as well as release for use in Manufacturing is the sole responsibility of Company. Novartis will not provide or transfer the parental cell line to Company at any time. In the event that it is
necessary for Company to access the parental cell line, Novartis will support Company by execution of these activities at the costs of Company and upon execution of a purchase order, either internally at Novartis or contracted to a Third Party, in
Novartis’s sole discretion and at Company’s sole cost. Novartis will assist Company to source the Novartis cell media, which is part of the Manufacturing Technology, from the Novartis supplier via a Letter of Authorization.

  

	7.	 COMMERCIALIZATION 

 

	7.1	 Commercialization. Company will be solely responsible for all aspects of Commercialization of the
Products, including planning and implementation, distribution, booking of sales, pricing, and reimbursement, at its sole cost and expense. 

  

	7.2	 Efforts. Company will itself, or through its Affiliates or sublicensees, use Commercially
Reasonable Efforts to Commercialize at least one Product, after obtaining Regulatory Approval. 

  
 20 

  

 Confidential Treatment Requested by Vera Therapeutics, Inc. 

Pursuant to 17 C.F.R. § 200.83 
  

	8.	 FINANCIAL PROVISIONS 

 

	8.1	 Initial Payment. In consideration of the licenses and rights granted to Company hereunder,
Company will make a one-time, non-refundable payment to Novartis in the amount of USD $5,000,000, via wire transfer, within fifteen days after the Effective Date.

  

	8.2	 Equity Consideration. In further consideration of the licenses and rights granted to Company
hereunder, Company shall issue certain securities to Novartis, as set forth in the Stock Purchase Agreement. 

  

	8.3	 Development and Regulatory Milestones. 

 

	 	(a)	 In further consideration of the licenses and rights granted to Company hereunder, upon achievement of
each of the following Milestones set forth below for any Product by Company, its Affiliates, or its sublicensees (as applicable), the corresponding Milestone Payments will be payable to Novartis: 

 

					
	 Development or Regulatory Milestone
	  	Milestone Payment (in
US Dollars)	 
	 [***]     [***]
	  	 	[***	] 
	 [***]     [***]
	  	 	[***	] 
	 [***]     [***]
	  	 	[***	] 
	 [***]     [***]
	  	 	[***	] 
	 [***]     [***]
	  	 	[***	] 
	 [***]     [***]
	  	 	[***	] 

  

	 	(b)	 The Specified Primary Endpoint will be considered “Achieved” when the Specified Primary
Endpoint has been met. 

  

	 	(c)	 Each Milestone Payment will be deemed earned as of the first achievement of the corresponding Milestone
and will be paid by Company to Novartis within [***] after it has been invoiced for the relevant Milestone Payment. Company will provide Novartis with written notice of the achievement of each Milestone within [***] after such Milestone is achieved.

  

	 	(d)	 In the event that a Milestone is achieved, but a Milestone Payment with respect to any previous
Milestone has not been paid by Company, then Company shall pay all such unpaid Milestone Payments with respect to such previous Milestone(s) at the same time that the Milestone Payment for the later Milestone is paid (a “Milestone Catch-Up Payment”); provided, however, that no Milestone Catch-Up Payment shall be made (i) in respect of Milestone 3 based upon the achievement of
Milestone 4; (ii) in respect of Milestone 3 or 4 based upon the achievement of Milestone 5, or (iii) in respect of Milestone 3, 4, or 5 based upon the achievement of Milestone 6, except in the case where [***] 

  
 21 

  

 Confidential Treatment Requested by Vera Therapeutics, Inc. 

Pursuant to 17 C.F.R. § 200.83 
  

	 	(e)	 Each Milestone in the table above will be paid only once. The total potential Milestone Payments that
may be paid under this Section 8.3 is [***]. 

  

	8.4	 Sales Milestones. 

 

	 	(a)	 Company will make each of the following one time payments the first time that worldwide Net Sales of all
Products in a given Calendar Year by it, its Affiliates, or their sublicensees meet the corresponding thresholds: 

  

					
	 Net Sales of Products in any Calendar Year during the Royalty

Term (in US
Dollars)                                        
                              
	  	Milestone
Payment
(in US Dollars)	 
	 [***]
	  	 	[***	] 
	 [***]
	  	 	[***	] 
	 [***]
	  	 	[***	] 

  

	 	(b)	 For example, if Net Sales of Products in the first Calendar Year of Net Sales equals [***]

  

	 	(c)	 Each Milestone Payment in the table above will be paid only once. The total potential Milestone Payments
that may be paid under this Section 8.4 is [***]. 

  

	 	(d)	 Each Milestone Payment will be deemed earned as of the first achievement of the corresponding sales
Milestone. Company will provide Novartis with written notice of the achievement of each Milestone within [***] after such sales milestone is achieved, and each Milestone Payment will be paid to Novartis within [***] after Company’s receipt of
the Invoice for the achievement of the relevant sales milestone. 

  

	8.5	 Royalty Payments. 

 

	 	(a)	 In consideration of the licenses and rights granted to Company hereunder, during the applicable Royalty
Term, Company will make royalty payments to Novartis on Net Sales of Products by Company, its Affiliates and sublicensees, at the rates set forth below: 

  

					
	 Aggregate Net Sales of Products

in any Calendar Year (in US Dollars)
	  	Royalty Rate	 
	 [***]
	  	 	[***	] 
	 [***]
	  	 	[***	] 
	 [***]
	  	 	[***	] 

  
 22 

  

 Confidential Treatment Requested by Vera Therapeutics, Inc. 

Pursuant to 17 C.F.R. § 200.83 
  

	 	(b)	 For example, if Net Sales of Products in a Calendar Year are [***], the royalty on such Net Sales will
be equal to [***] 

  

	 	(c)	 Following the expiration of the applicable Royalty Term for a Product in a country, the license granted
to Company under Section 2.1 of this Agreement with respect to such Product in such country will continue in effect, but will become non-exclusive, fully paid-up, royalty-free, perpetual and irrevocable. 

  

	 	(d)	 Within [***] Company will provide to Novartis a Sales & Royalty Report. Novartis will submit an
Invoice to Company with respect to the royalty amount shown therein. Company will pay such royalty amount within [***] after receipt of the Invoice. 

  

	8.6	 Know-How Royalty; Loss of Market Exclusivity; Third Party
Obligations. 

  

	 	(a)	 If the Royalty Term for a Product in a country continues solely due to (i) clause (b)
(or clauses (b) and (c)) of the definition of Royalty Term then the royalties payable by Company to Novartis for Net Sales of such Product in such country will thereafter be reduced by [***], or (ii) clause (c) of the definition of
Royalty Term then the royalties payable for Net Sales of such Product in such country will thereafter be reduced by [***]. 

  

	 	(b)	 If a Loss of Market Exclusivity exists with respect to such Product in such country, and
(i) the Net Sales of such Product in that country in a Calendar Quarter are at least [***] unless Novartis can demonstrate that such reduction is not attributable in material part to the Loss of Market Exclusivity, then the royalties
payable by Company to Novartis with respect to Net Sales of such Product in such country will thereafter be reduced by [***], (ii) the Net Sales of such Product in that country in a Calendar Quarter are at least [***] less than the average
Net Sales of such Product in that country during the last complete Calendar Quarter immediately preceding the launch of such Biosimilar Product, unless Novartis can demonstrate that such reduction is not attributable in material part to the Loss of
Market Exclusivity, then the royalties payable by Company to Novartis with respect to such Net Sales of such Product in such country will thereafter be reduced by [***], or (iii) the Net Sales of such Product in that country in a
Calendar Quarter are at least [***] less than the average Net Sales of such Product in that country during the last complete Calendar Quarter immediately preceding the launch of such Biosimilar Product, unless Novartis can demonstrate that such
reduction is not attributable in material part to the Loss of Market Exclusivity, then the royalties payable by Company to Novartis with respect to such Net Sales of such Product in such country will thereafter be reduced by [***]. For clarity, only
one of each of the foregoing clauses (i) through (iii) of this Section 8.6(b) shall be applicable at any time. 

  

	 	(c)	 If Company reasonably determines that, in order to avoid infringement of any Patent Right not licensed
hereunder that covers any Antibody or Product in a country, and Company or any of its Affiliates or sublicensees acquires or licenses such rights from 

  
 23 

  

 Confidential Treatment Requested by Vera Therapeutics, Inc. 

Pursuant to 17 C.F.R. § 200.83 
  

	 	
a Third Party and is required to pay a royalty to such Third Party, Company will have the right to deduct [***] of such royalty payments actually paid by Company or its Affiliate or sublicensee
to such Third Party under such license from the royalty due with respect to any Product incorporating such Antibody to Novartis under Section 8.5. 

  

	 	(d)	 The reductions and deductions set forth in this Section 8.6 are cumulative and shall apply, in
each case, to the maximum extent applicable; provided, that in no event will any royalty payment due to Novartis from Company under Section 8.5(a) in a given country in a given Calendar Quarter be reduced by more than (x) [***] through
operation of Sections 8.6(a), 8.6(b)(i) and 8.6(c) or (y) [***] through operation of Sections 8.6(a), 8.6(b)(iii) and 8.6(c). 

  

	 	(e)	 Any reduction pursuant to Section 8.6(a) or 8.6(b) of the royalties payable by
Company to Novartis with respect to Net Sales of a particular Product in a particular country under Section 8.5(a) will be calculated as follows: 

 

	 	(i)	 First, the effective, or “blended,” royalty rate applicable to worldwide aggregate annual Net
Sales of such Product (excluding Net Sales of any Product in any country that occur after the date of the expiration of the Royalty Term for such Product in such country) will be determined by dividing: (x) the total amount of
royalties that would be payable under Section 8.5(a) with respect to worldwide aggregate annual Net Sales of all Products (excluding Net Sales of any Product in any country that occur after the date of the expiration of the
Royalty Term for such Product in such country), without giving effect to any royalty reduction or adjustment that may be available under Section 8.6(a) or 8.6(b); by (y) the total
amount of worldwide aggregate annual Net Sales of all Products (excluding Net Sales of any Product in any country that occur after the date of the expiration of the Royalty Term for such Product in such country); expressed as a percentage (such
percentage, the “Effective Royalty Rate”). [***] 

  

	 	(ii)	 Any available royalty reduction under Section 8.6(a) or 8.6(b) with
respect to Net Sales of a particular Product in a particular country would be calculated by applying (x) the applicable percentage reduction under the relevant provision of Section 8.6(a) or 8.6(b), to
(y) the amount of royalties determined by multiplying the Net Sales of such Product in such country by the Effective Royalty Rate. 

  

	8.7	 Sublicense Consideration 

 

	 	(a)	 In addition to the other payment obligations of Company hereunder, in further consideration for the
license and other rights granted to Company hereunder, Company shall pay to Novartis the Sublicense Percentage of any up-front, milestone, or other payments received by Company or its Affiliates as consideration for the grant of any sublicense
hereunder, excluding [***] For clarity, in a case where the Company receives payments from a sublicensee in a given Calendar Quarter in respect of an 

  
 24 

  

 Confidential Treatment Requested by Vera Therapeutics, Inc. 

Pursuant to 17 C.F.R. § 200.83 
  

	 	
interest in a profit-share or similar payments based on Product revenues, such payments will be considered Sublicense Consideration, but the amount payable to Novartis under this
Section 8.7(a) in respect thereof will be reduced by [***] 

  

	 	(b)	 Notwithstanding Section 8.7(a), in the case of any milestone payments received
by Company or its Affiliates from a sublicensee in respect of achievement of the milestones set forth in Sections 8.3 and 8.4, Company shall pay to Novartis the greater of (i) the Sublicense Percentage of the milestone
payment received by Company or its Affiliate from such sublicensee, or (ii) the Milestone Payment set forth in Section 8.3 or 8.4, as applicable. If Company receives a milestone payment from a sublicensee
for milestones not included in Section 8.3 or 8.4, Novartis shall be entitled to receive the Sublicense Percentage of such milestone payments, without offset or reduction of any Milestone Payment under
Section 8.3 or 8.4. 

  

	 	(c)	 Within [***] Company will provide notice to Novartis thereof. Novartis will submit an Invoice to Company
with respect to the Sublicense Consideration payable in respect thereof, and Company will pay such Sublicense Consideration within [***]. 

  

	8.8	 Payments. 

  

	 	(a)	 All payments from Company to Novartis will be made by wire transfer in US Dollars to the credit of such
bank account as may be designated by Novartis in this Agreement or in writing to Company. Any payment which falls due on a date which is not a business day in the location from which the payment may be made is payable on the next succeeding business
day in such location. Unless otherwise provided in this Agreement, all amounts payable hereunder will be due [***] after such amounts accrue. 

  

	 	(b)	 All payments under this Agreement will be payable in US Dollars. When conversion of payments from any
foreign currency is required to be undertaken by Company, the US Dollar equivalent will be calculated using Company’s then-current standard exchange rate methodology as applied in its external reporting. If there is no standard exchange
rate methodology applied by Company in its external reporting in accordance with Accounting Standards, then any amount in a currency other than US Dollars shall be converted to US Dollars using the exchange rate most recently quoted in the Wall
Street Journal in New York as of the last Business Day of the applicable Calendar Quarter. 

  

	 	(c)	 Other than as provided in this Section 8.8(c), each Party shall be responsible
for its own Taxes, including any Tax, fee, assessment or other charge based on or measured by the capital or net income, or any other Tax imposed by any jurisdiction. Each Party will reasonably assist the other Party in lawfully claiming exemptions
from and minimizing such deductions or withholdings under double taxation laws or similar circumstances. To the extent such exemptions are unavailable, Company shall be entitled to deduct and withhold (or cause to be deducted or withheld) from any
consideration payable or otherwise deliverable pursuant to this Agreement, such amounts as are required to be deducted or withheld therefrom under any provision of 

  
 25 

  

 Confidential Treatment Requested by Vera Therapeutics, Inc. 

Pursuant to 17 C.F.R. § 200.83 
  

	 	
U.S. federal, state, local or non-U.S. Tax law or under any applicable legal requirement. To the extent such amounts are deducted or withheld and paid over
to the appropriate governmental authority, such amounts shall be treated for all purposes under this Agreement as having been paid to the Person to whom such amounts would otherwise have been paid. To the extent that such amounts are not so deducted
and withheld, Company shall indemnify Novartis and its Affiliates for any amounts imposed on Novartis or such Affiliate by a governmental entity, together with any related Losses. Additionally, all charges made hereunder for the supply of Product by
Novartis to Company is exclusive of any sales, use, value added or similar tax customarily borne by a purchaser, which will be the exclusive responsibility of Company. 

 

	 	(d)	 Without limiting any other rights or remedies available to Novartis hereunder, if Company does not pay
any amount due on or before the due date, any such payment shall bear interest at a rate of [***] computed from the date such payment was due until the date Company makes the payment. 

 

	8.9	 Records and Audit Rights. 

 

	 	(a)	 Company will keep, and will cause its Affiliates and sublicensees to keep, complete, true and accurate
books and records in accordance with its Accounting Standards in relation to Net Sales and royalties payable to Novartis hereunder. Company will keep, and will cause its Affiliates and sublicensees to keep, such books and records for at least [***]
following the delivery of the Sales & Royalty Report for the Calendar Quarter to which they pertain. 

  

	 	(b)	 Novartis may, upon written notice to Company, appoint an internationally-recognized independent
accounting firm (which is reasonably acceptable to Company) (the “Auditor”) to inspect the relevant reports, statements, records or books of accounts (as applicable) of Company or its Affiliates or sublicensees to verify the
accuracy of any Sales & Royalty Report. Before beginning its audit, the Auditor will execute an undertaking reasonably acceptable to Company by which the Auditor will keep confidential all Confidential Information reviewed during such
audit. The Auditor will have the right to disclose to Novartis its conclusions regarding any payment owed under this Agreement. 

  

	 	(c)	 Company will, and will cause its Affiliates and sublicensees to, make their records available for
inspection by such Auditor during regular business hours at such place or places where such records are customarily kept, upon receipt of reasonable advance notice from Novartis. The records will be reviewed solely to verify the accuracy of the
Sales & Royalty Reports. Such inspection right will not be exercised more than [***] and not more frequently than [***]. In addition, Novartis will only be entitled to audit the relevant books and records of Company
relating to a Sales & Royalty Report for a period of [***] after receipt of the applicable Sales & Royalty Report. Novartis will hold in confidence in accordance with Section 10 all Confidential Information received
and all Confidential Information learned in the course of any audit or inspection, except to the extent necessary to enforce its rights under this Agreement or if disclosure is required by Applicable Law. 

  
 26 

  

 Confidential Treatment Requested by Vera Therapeutics, Inc. 

Pursuant to 17 C.F.R. § 200.83 
  

	 	(d)	 The Auditor will provide its audit report and basis for any determination to Company at the time such
report is provided to Novartis, before it is considered final. 

  

	 	(e)	 In the event that the final result of the inspection reveals an undisputed underpayment or overpayment
by Company, the underpaid or overpaid amount will be settled promptly. 

  

	 	(f)	 Novartis will pay for any such audits, as well as its own expenses associated with enforcing its rights
with respect to any payments hereunder, except that in the event there is any upward adjustment in aggregate amounts payable for any Calendar Quarter shown by such audit of more than [***] of the amount paid, Company will pay for such audit.

  

	8.10	 No Projections. Novartis and Company acknowledge that nothing in this Agreement will be construed as
representing an estimate or projection of anticipated sales of any Product, and that the Milestones and Net Sales levels set forth above or elsewhere in this Agreement or that have otherwise been discussed by the Parties are merely intended to
define the Milestone Payments and royalty obligations to Novartis in the event such Milestones or Net Sales levels are achieved. 

  

	9.	 INTELLECTUAL PROPERTY. 

 

	9.1	 Inventions and Know-How. All inventions, whether
or not reduced to practice, and Know-How, including data and results, arising from activities conducted by or on behalf of a Party under this Agreement, including any Patent Rights covering such inventions
that arise from such activities after the Effective Date, will be owned by such Party. 

  

	9.2	 Patent Prosecution and Maintenance Following the Effective Date. 

 

	 	(a)	 Company will control prosecution and maintenance of the Novartis Patents at Company’s sole cost and
expense, using counsel reasonably acceptable to Novartis. Company will regularly consult with Novartis regarding important issues relating to the prosecution and maintenance of the Novartis Patents, and will furnish to Novartis copies of documents
materially relevant to such prosecution and maintenance in sufficient time, but no later than [***], prior to the filing of such document to allow for review and comment by Novartis, and Company will reasonably consider all of such comments.

  

	 	(b)	 Company will notify Novartis of any decision not to continue to pay the expenses of prosecution and
maintenance of any Novartis Patent, which notice must be delivered within [***] or any other due date that requires action in connection with such Patent Right. In such event, Company shall permit Novartis, at its sole discretion and expense, to
file or to continue prosecution or maintenance of such Patent Right. If Novartis undertakes such prosecution and maintenance, (c) Company will provide Novartis all reasonable assistance and cooperation in relation thereto, including
providing any 

  
 27 

  

 Confidential Treatment Requested by Vera Therapeutics, Inc. 

Pursuant to 17 C.F.R. § 200.83 
  

	 	
necessary powers of attorney and any other required documents or instruments to effect such transfer, and (b) the license granted to Company to such Novartis Patent in such country
shall thereupon terminate. 

  

	 	(d)	 Each Party will be solely responsible for filing, prosecuting, and maintaining all Patent Rights under
intellectual property arising from such Party’s activities under this Agreement and solely owned by such Party, at its own cost and expense. 

  

	 	(e)	 For the avoidance of doubt, the provisions of this Section 9.2 relate solely
to Novartis Patents other than Manufacturing Patents. Novartis retains all rights and obligations to maintain and prosecute Manufacturing Patents. 

  

	9.3	 Third Party Infringement. 

 

	 	(a)	 Each Party will promptly notify the other of any actual, suspected, or threatened infringement by a
Third Party of any of the Novartis Patents or misappropriation of any Novartis Know-How of which it becomes aware, including any “patent certification” filed in the United States under 21 U.S.C.
§355(b)(2) or 21 U.S.C. §355(j)(2) or similar provisions in other jurisdictions, of any declaratory judgment, opposition, or similar action alleging the invalidity, unenforceability, or
non-infringement of any Novartis Patents, or any filing of any abbreviated Regulatory Filing for a Biosimilar Product in any jurisdiction. Each Party shall provide the other Party with all available evidence
supporting such infringement, suspected infringement, unauthorized use or misappropriation or suspected unauthorized use or misappropriation (collectively, “Third Party Infringement”). 

 

	 	(b)	 Company will have the first right, but not the obligation, to bring and control any legal action in
connection with Third Party Infringement at its own expense as it reasonably determines appropriate, and Novartis shall have the right, at its own expense, to be represented in any such action by counsel of its own choice. If Company fails to bring
an action or proceeding with respect to, or to terminate infringement of, any Novartis Patent [***], Novartis will have the right to bring and control any such action at its own expense and by counsel of its own choice, and Company will have
the right, at its own expense, to be represented in any such action by counsel of its own choice; provided, however, that if Company notifies Novartis in writing prior to [***] then Company shall be obligated to file such action before
the time limit, and Novartis will not have the right to bring and control such action. 

  

	 	(c)	 At the request of the Party controlling the Third Party Infringement claim, the other Party will provide
assistance in connection therewith, including by executing reasonably appropriate documents, access to such Party’s premises and employees, cooperating reasonably in discovery and joining as a party to the action if required.

  

	 	(d)	 In connection with any such proceeding, neither Party will enter into any settlement admitting the
invalidity of, or otherwise impairing the other Party’s rights in, the Novartis Technology without the prior written consent of the other Party, which will not be unreasonably withheld or delayed. 

  
 28 

  

 Confidential Treatment Requested by Vera Therapeutics, Inc. 

Pursuant to 17 C.F.R. § 200.83 
  

	 	(e)	 Any recoveries resulting from such an action relating to a Third Party Infringement will be first
applied against payment of each Party’s costs and expenses in connection therewith. In the event that Company brought such action, any remainder will be retained by Company; provided, however, any such amount will be considered Net Sales
hereunder and will be subject to the royalties and Net Sales Milestones payable to Novartis under this Agreement. In the event that Novartis brought such action, the remainder will be retained by Novartis. 

 

	9.4	 Third Party Patent Invalidity Claim. If a Third Party at any time asserts a claim that any
Novartis Patent is invalid or otherwise unenforceable (an “Invalidity Claim”), whether as a defense in an infringement action brought by a Party pursuant to Section 9.4, in a declaratory judgment action or any patent
office proceeding anywhere in the world (e.g., inter-partes review or European opposition), Company shall have the first right, but not the obligation, to defend such Invalidity Claim and Novartis shall cooperate with Company in preparing and
formulating a response to such Invalidity Claim. If Company does not defend an Invalidity Claim brought against a Novartis Patent, Novartis may defend such Invalidity Claim and the coordination provisions of Section 9.3(c) will apply to
such Invalidity Claim, mutatis mutandis as they apply to Third Party Infringement suits. No Party may, without the consent of the other Party, settle or compromise any Invalidity Claim in any manner which would (a) have an adverse
effect on such other Party’s rights or obligations hereunder or (b) be an admission of liability on behalf of the other Party; provided, however, that the Party initiating such suit may settle such suit without
such consent if such settlement involves only the receipt of money from, or the payment of money to, such Third Party and the Party settling such suit makes all such payments to such Third Party. To the extent such Invalidity Claim is raised as a
defense in an infringement action brought by a Party pursuant to Section 9.3, the expense provisions of Section 9.3 will apply and counsel to the Party controlling the infringement action shall act as the ministerial liaison with
the court. 

  

	9.5	 Company Patent Invalidity Claim. The Parties have determined the value of the Novartis Technology
based on their understanding of the validity and enforceability of the relevant Patent Rights and Know-How. If Company or any Affiliate thereof at any time asserts an Invalidity Claim in a declaratory judgment
action or any patent office proceeding anywhere in the world and such challenge does not result in a material diminution of the scope of the relevant Novartis Patent, then the terms of this Agreement shall continue in full force and effect, but all
payment amounts set forth in Section 8.3, Section 8.4, and Section 8.5 shall be multiplied by [***]. 

 

	9.6	 Defense of Infringement Claims by Third Parties. If any Third Party asserts a claim,
demand, action, suit or proceeding against a Party (or any of its Affiliates), alleging that any Product (other than with respect to the use or practice of the Manufacturing Technology) or the use or practice of the Novartis Technology infringes,
misappropriates or violates the intellectual property rights of any Person (any such claim, demand, action, suit or proceeding being referred to as an “Infringement Claim”), the Party first having notice of the Infringement

  
 29 

  

 Confidential Treatment Requested by Vera Therapeutics, Inc. 

Pursuant to 17 C.F.R. § 200.83 
  

	 	
Claim shall promptly notify the other Party thereof in writing specifying the facts, to the extent known, in reasonable detail and the following shall apply: 

 

	 	(a)	 In the case of any such Infringement Claim against either Party individually or against both Novartis
and Company, in each case, with respect to the Product, Company shall assume control of the defense of such Infringement Claim. Novartis, upon the request of Company and if required by Applicable Law, will join in any such litigation at
Company’s expense, and in any event to reasonably cooperate with Company at Company’s expense. Novartis will have the right to consult with Company concerning such Infringement Claim and to participate in and be represented by independent
counsel in any litigation in which Company is a party, at its own expense. Company shall not have the right to settle any Infringement Claim to the extent such settlement would adversely affect Novartis rights in and to the Novartis Technology or
Manufacturing Technology without the written consent of Novartis, not to be unreasonably withheld, conditioned or delayed. 

  

	 	(b)	 During the period in which such Infringement Claim is pending and following the resolution thereof,
Company shall bear all costs incurred in connection therewith (including litigation costs, attorneys’ fees, costs of settlement) including damage awards, and any other payment resulting therefrom. In the event Company is required to obtain a
license from any Third Party under any patent or other intellectual property right of such Third Party, Company shall be solely responsible for any costs, fees, royalties, damages or other payments associated with such license.

  

	9.7	 Trademarks. Company will have the right to brand the Products using Company related trademarks
and any other trademarks and trade names it determines appropriate for the Products, which may vary by country or within a country (“Product Marks”). Company will own all rights in the Product Marks and register and maintain the
Product Marks in the countries and regions it determines reasonably necessary. 

  

	9.8	 Patent Extensions. 

 

	 	(a)	 If requested by Company, Novartis will cooperate in obtaining patent term restoration (including under
the Drug Price Competition and Patent Term Restoration Act), supplemental protection certificates or their equivalents, and patent term extensions with respect to the Novartis Patents in any country or region where applicable. Novartis will provide
all reasonable assistance requested by Company, including permitting Company to proceed with applications for such in the name of Novartis, if deemed appropriate by Company, and executing documents and providing any relevant information to Company.

  

	 	(b)	 As between the Parties, Company will in its sole discretion determine which, if any, Novartis Patents,
it will apply to extend; provided, however, that Company will give Novartis [***] before doing so and reasonably consider any input from Novartis with respect to the extension of any Novartis Patents. 

 

	10.	 CONFIDENTIALITY AND PUBLICITY 

 

	10.1	 Duty of Confidence. Subject to the other provisions of this Article 10, all Confidential
Information disclosed by a Party or its Affiliates under this Agreement will be maintained in 

  
 30 

  

 Confidential Treatment Requested by Vera Therapeutics, Inc. 

Pursuant to 17 C.F.R. § 200.83 
  

	 	
confidence and otherwise safeguarded by the recipient Party. The recipient Party may only use the Confidential Information for the purposes of this Agreement and pursuant to the rights granted to
the recipient Party under this Agreement. Subject to the other provisions of this Article 10, each Party will hold as confidential such Confidential Information of the other Party or its Affiliates in the same manner and with the same
protection as such recipient Party maintains its own confidential information, but in no event using less than reasonable care. Subject to the other provisions of this Article 10, a recipient Party may only disclose Confidential Information
of the other Party to employees, agents, contractors, consultants and advisers of the Party and its Affiliates and sublicensees and to Third Parties to the extent reasonably necessary for the purposes of, and for those matters undertaken pursuant
to, this Agreement; provided that such Persons are bound to maintain the confidentiality of the Confidential Information in a manner consistent with the confidentiality provisions of this Agreement. 

 

	10.2	 Exceptions. The obligations under this Article 10 will not apply to any Confidential
Information to the extent the recipient Party can demonstrate by competent evidence that such Confidential Information: 

  

	 	(a)	 is (at the time of disclosure) or becomes (after the time of disclosure) known to the public or part of
the public domain through no breach of this Agreement by the recipient Party or its Affiliates; 

  

	 	(b)	 was known to, or was otherwise in the possession of, the recipient Party or its Affiliates prior to the
time of disclosure by the disclosing Party or any of its Affiliates; 

  

	 	(c)	 is disclosed to the recipient Party or an Affiliate on a
non-confidential basis by a Third Party who is entitled to disclose it without breaching any confidentiality obligation to the disclosing Party or any of its Affiliates; or 

 

	 	(d)	 is independently developed by or on behalf of the recipient Party or its Affiliates, as evidenced by its
written records, without reference to the Confidential Information disclosed by the disclosing Party or its Affiliates under this Agreement. 

Specific aspects or details of Confidential Information will not be deemed to be within the public domain or in the possession of the recipient
Party merely because the Confidential Information is embraced by more general information in the public domain or in the possession of the recipient Party. Further, any combination of Confidential Information will not be considered in the public
domain or in the possession of the recipient Party merely because individual elements of such Confidential Information are in the public domain or in the possession of the recipient Party unless the combination and its principles are in the public
domain or in the possession of the recipient Party. 
  

	10.3	 Authorized Disclosures. 

 

	 	(a)	 In addition to disclosures allowed under Sections 10.1 and 10.2, and except as set forth
in Section 2.5, either Party may disclose Confidential Information belonging to the other Party or its Affiliates to the extent such disclosure is necessary in the following instances: (i) filing or prosecuting
Patent Rights as permitted by this Agreement; (ii) in 

  
 31 

  

 Confidential Treatment Requested by Vera Therapeutics, Inc. 

Pursuant to 17 C.F.R. § 200.83 
  

	 	
connection with Regulatory Filings for Products; (iii) prosecuting or defending litigation as permitted by this Agreement; (iv) complying with Applicable Law or the
inquiries of Regulatory Authorities; (v) to a bona fide potential acquirer, investor, collaborator, partner, sublicensee under reasonable and customary written confidentiality obligations; or (vi) otherwise to the
extent otherwise necessary or appropriate in connection with exercising the license and other rights granted to or performing the obligations imposed on such Party hereunder. Notwithstanding anything in this Agreement to the contrary, each Party
will be entitled to disclose, without the consent of or any notification to the other Party, any pharmacovigilance information originating from itself, its Affiliates, and the other Party to Regulatory Authorities, investigators, ethical committees
and internal review boards, and any other Third Parties that have a need to know such information according to each Party’s Risk Management and Adverse Event Reporting requirements. 

 

	 	(b)	 Novartis will be entitled to publish with respect to research and Development of any Antibody or Product
with Company’s prior written consent (such consent not to be unreasonably withheld, conditioned or delayed). Company acknowledges that certain Third Parties (e.g., academic institutions that have received an Antibody from Novartis) may
have the right to publish information relating to Antibodies or Products, and any such disclosure will not be deemed to be a breach of Novartis’ obligations of confidentiality, provided that Novartis provides notice of such publication
to Company and seeks the Company’s prior written consent to such publication (such consent not to be unreasonably withheld, conditioned or delayed), in each case, to the extent Novartis or any of its Affiliates has notice or consent rights with
respect to such publication by such Third Party.  

  

	 	(c)	 Company will be entitled to publish with respect to research and Development of any Antibody or Product
without consent of Novartis, provided that if such publication contains Confidential Information of Novartis, Company shall obtain Novartis’ prior written consent (such consent not to be unreasonably withheld, conditioned or delayed).

  

	 	(d)	 In the event the recipient Party is required to disclose Confidential Information of the disclosing
Party by Applicable Law or in connection with a bona fide legal process, such disclosure will not be a breach of this Agreement; provided that the recipient Party (i) informs the disclosing Party as soon as reasonably
practicable of the required disclosure; (ii) limits the disclosure to the required purpose; and (iii) at the disclosing Party’s request and expense, assists in an attempt to object to or limit the required disclosure or
to otherwise receive “confidential” or “trade secret” treatment with respect to relevant portions of such disclosure. 

  

	10.4	 Ongoing Obligation for Confidentiality. The provisions of this Article 10 shall survive the
termination or expiration of this Agreement in accordance with Section 12.2. Upon early termination of this Agreement for any reason, each Party and its Affiliates will immediately return to the other Party or destroy any Confidential
Information disclosed by the other Party, except for one copy which may be retained in its confidential files for archive purposes and except as otherwise required by Applicable Law. 

  
 32 

  

 Confidential Treatment Requested by Vera Therapeutics, Inc. 

Pursuant to 17 C.F.R. § 200.83 
  

	10.5	 Publicity. Neither Party shall issue any other press release, trade announcement or make any
other public announcement or statement with regard to the transactions contemplated by this Agreement without the other Party’s prior written consent, except as such announcement or statement may be required, based upon the reasonable advice of
counsel, by Applicable Law or the rules and regulations of any stock exchange upon which the securities of Novartis or Company or their respective direct or indirect parent entities are listed, or the requirements of any self-regulatory body, in
which case the Party requested to make the statement or announcement shall, to the extent reasonably practicable under the circumstances, allow the other Party reasonable time to review and comment upon such statement or announcement in advance of
such issuance. Without limiting the foregoing, to the extent any Party is obligated by Applicable Law to file a copy of this Agreement with the SEC or other governmental authority, such Party shall provide the other Party with reasonable opportunity
to review and request confidential treatment of portions of this Agreement pursuant to Applicable Law (including the Securities Exchange Act of 1934 and the Freedom of Information Act and the rules promulgated thereunder) by means of filing a copy
of this Agreement redacted to remove such terms as are reasonably requested by the other Party. The Party so obligated shall give due consideration to the other Party’s request, and, if agreed by the Parties, use reasonable efforts to obtain
such confidential treatment or permission to redact such exhibit. 

  

	11.	 TERM AND TERMINATION 

 

	11.1	 Term. The term of this Agreement (the “Agreement Term”) will commence upon the
Effective Date and continue on a Product-by-Product and country-by-country basis until the expiry of the Royalty Term for such Product in such country, unless earlier
terminated as permitted by this Agreement. 

  

	11.2	 Termination for Cause. If either Novartis or Company is in material breach of any material
obligation hereunder, the non-breaching Party may give written notice to the breaching Party specifying the claimed particulars of such breach, and in the event such material breach is not cured within [***]
after such notice ([***] in the case of breach of a payment obligation), the non-breaching Party will have the right (but not the obligation) thereafter to terminate this Agreement immediately by giving
written notice to the breaching Party to such effect. Any termination by any Party under this Section and the effects of termination provided herein will be without prejudice to any damages or other legal or equitable remedies to which it may be
entitled. The right to terminate in accordance with this Section 11.2 may be exercised on a Product-by-Product or country-by-country basis. 

  

	11.3	 Insolvency. If an Insolvency Event occurs, (a) Company will give immediate (but in
any event, not longer than [***]) notice to Novartis of such occurrence, and (b) Novartis will have the right to immediately terminate this Agreement by written notice to Company.  

 

	11.4	 Termination by Company Without Cause. Company may terminate this Agreement without cause at any time
after the Effective Date in its entirety or on a Product-by-Product or country-by-country
basis at any time on 60 days’ prior written notice. 

  
 33 

  

 Confidential Treatment Requested by Vera Therapeutics, Inc. 

Pursuant to 17 C.F.R. § 200.83 
  

	12.	 EFFECT OF TERMINATION 

 

	12.1	 Effect of Termination. Upon termination of this Agreement by either Party for any reason, in its
entirety or with respect to a Product or country, except in each case for any Product in any country that is subject to a perpetual and irrevocable license pursuant to Section 8.5(c): 

 

	 	(a)	 as of the effective date of the termination (the “Termination Date”), all licenses and
other rights granted by Novartis to Company under the Novartis Technology and Manufacturing Technology will terminate with respect to the Terminated Product in the Terminated Territory, and Company shall not have any rights to use or exercise any
rights under the Novartis Technology or Manufacturing Technology with respect to the Terminated Product in the Terminated Territory, and the sole right to prosecute and maintain all Novartis Patents with respect to the Terminated Product in the
Terminated Territory shall be transferred to Novartis; provided that any sublicense granted by Company under the license set forth in Section 2.1 in the applicable Terminated Territory shall survive the termination
of this Agreement and become a direct license from Novartis to such sublicensee, provided further that, in the case of termination for Company’s uncured material breach pursuant to Section 11.2, such sublicensee
did not cause such uncured material breach of this Agreement, and provided further that Novartis shall have no obligations under such sublicense beyond its obligations set forth in this Agreement; 

 

	 	(b)	 at Novartis’ written request, which must be delivered to Company not later than [***] after receipt
of the applicable notice of termination, the following provisions shall apply, except in the event of termination by Company pursuant to Section 11.2: 

 

	 	(i)	 within [***] after receipt of such notice, Company will provide to Novartis a fair and accurate summary
report of the status of the research, Development and Commercialization of the Terminated Product in each country in the Terminated Territory through the Termination Date; 

 

	 	(ii)	 Company will grant, and hereby does grant (effective on delivery of the notice), and will cause its
Affiliates (and use Commercially Reasonable Efforts to cause its sublicensees, to the extent such sublicensees are not granted a direct license pursuant to Section 12.1(a)) to grant, to Novartis, solely for the Development
and Commercialization of Terminated Products in the Field in the Terminated Territory, a perpetual, irrevocable, exclusive license in the Terminated Territory, with the right to grant sublicenses, under all Patent Rights and Know-How Controlled by Company and its Affiliates (and sublicensees, to the extent such sublicensees have agreed to grant such license and are not granted a direct license pursuant to
Section 12.1(a)) as of the Termination Date that are specifically related to, and actually used and applied as of the Termination Date in the Development and Commercialization of the Terminated Products, to Develop, and
Commercialize the Terminated Products in the Terminated Territory; provided that with respect to any Patent Rights and Know-How that are Controlled by Company and its Affiliates (and sublicensees, to
the extent such sublicensees have agreed to grant such license and are not granted a direct 

  
 34 

  

 Confidential Treatment Requested by Vera Therapeutics, Inc. 

Pursuant to 17 C.F.R. § 200.83 
  

	 	
license pursuant to Section 12.1(a)) pursuant to an agreement with a Third Party, Novartis will pay all amounts due under any such agreement as a result of
Novartis’ exercise of the rights granted thereunder and Novartis’ rights will be subject to the terms of the applicable Third Party agreement. 

  

	 	(iii)	 within [***] after receipt of such notice, to the extent permitted by Applicable Law, Company will, and
will cause its Affiliates to, provide Novartis or its designee, solely for the Development and Commercialization of Terminated Products in the Field in the Terminated Territory, an electronic copy of all documentation within the Know-How licensed to Novartis pursuant to Section 12.1(b)(ii); provided that if any such documentation is not available in electronic format, Company shall use its Commercially Reasonable Efforts
to provide a hard copy of such documentation [***] after receipt of such notice; provided further that the Parties acknowledge that the disclosure by Company of such Know-How will consist of the disclosure of data residing in Company’s
databases, and will not include any database architecture or require any experimental work performed by Company for the purpose of technology transfer; 

  

	 	(iv)	 to the extent permitted by Applicable Law, Company will, and will cause its Affiliates (and use
Commercially Reasonable Efforts to cause its sublicensees, to the extent such sublicensees are not granted a direct license pursuant to Section 12.1(a)) to, promptly transfer to Novartis or its designee all Regulatory
Filings, Regulatory Approvals and Pricing Reimbursement Approvals, the contents of any global safety database, records of all interactions with Regulatory Authorities, in each case to the extent solely related to Terminated Products in the
Terminated Territory, that Company and its Affiliates (and sublicensees, to the extent such sublicensees have agreed to grant such license and are not granted a direct license pursuant to Section 12.1(a)) Control as of the
Termination Date; provided, however, that if Company is restricted under Applicable Law from transferring ownership of any of the foregoing items to Novartis or its designee, Company shall grant, and hereby does grant, and will cause its
Affiliates (and use Commercially Reasonable Efforts to cause its sublicensees, to the extent such sublicensees are not granted a direct license pursuant to Section 12.1(a)) to grant, to Novartis (or its designee) a right of
reference or use to such item. Company will take all permitted actions reasonably necessary to effect such transfer or grant of right of reference or use to Novartis or its designee; 

 

	 	(v)	 to the extent reasonably requested by Novartis [***] after receipt of such notice, Company will use
Commercially Reasonable Efforts to assign or transfer to Novartis any license agreements or other contracts between Company or any of its Affiliates and any Third Party to the extent solely related to the Terminated Products in the Terminated
Territory (including, as applicable, clinical trial and manufacturing agreements), to the extent such agreements are in effect as of Termination Date and such assignment or transfer is permitted, and to facilitate introductions of Novartis to the
applicable subcontractors, licensors, manufacturing vendors, clinical trial sites, clinical trial investigators and the like; 

  
 35 

  

 Confidential Treatment Requested by Vera Therapeutics, Inc. 

Pursuant to 17 C.F.R. § 200.83 
  

	 	(vi)	 to the extent requested by Novartis [***]after receipt of such notice, Novartis will have the right to
purchase from Company all of the inventory of the Terminated Products held by Company and its Affiliates for use in the Terminated Territory as of the Termination Date at a price equal to Company’s actual, fully-burdened manufacturing cost,
determined in accordance with Accounting Standards, plus, in the case of termination by the Company pursuant to Sections 11.2 or 11.3, a mark-up of [***]; and 

 

	 	(vii)	 for a period of [***] following receipt of such notice, Company will provide such assistance as may be
reasonably necessary to transfer manufacturing documents and materials that are Controlled by Company and its Affiliates (or their subcontractor(s)) and actually used as of the Termination Date in the manufacture of Terminated Products for use in
the Field in the Terminated Territory, and cooperate with Novartis in reasonable respects to transfer to Novartis, or Novartis’ designated contract manufacturer, the manufacturing technologies (including all relevant Know-How) that are used in the manufacture of the Terminated Products for use in Field in the Terminated Territory, in each case, in the manner set forth in Section 4.2 as if Novartis were Company and Company
were Novartis, mutatis mutandis; 

  

	 	(c)	 except as set forth in this Section 12.1 and in Section 12.2, the rights and
obligations of the Parties hereunder will terminate as of the Termination Date; and 

  

	 	(d)	 Company shall return to Novartis or, on Novartis’s request, destroy all records and materials in
its possession or control that contain or comprise Novartis Know-How, Manufacturing Know-How, or other Confidential Information of Novartis solely related to the
Terminated Product in the Terminated Territory, except for one copy which may be retained in its confidential files for archive purposes and except as otherwise required by Applicable Law. 

 

	12.2	 Survival. Expiration or termination of this Agreement will not relieve the Parties of any
obligation accruing prior to such expiration or termination. Without limiting the foregoing, the provisions of Article 1, Sections 2.3 (except for the Non-Compete), 2.4, 2.5, 4.3, 4.4, 6.2,
8.8 (as specified therein), 8.9, 9.1, 11.2 (but only the last sentence thereof), Article 12, Section 13.6, Article 14, and Article 15 will survive expiration or termination of this
Agreement. The provisions of Article 10 (Confidentiality) will survive the termination or expiration of this Agreement for a period of [***]. 

  

	12.3	 Termination Not Sole Remedy. Termination is not the sole remedy under this Agreement and, whether or not
termination is effected and notwithstanding anything contained in this Agreement to the contrary, all other remedies will remain available except as agreed to otherwise herein. Nothing in this Agreement shall obligate a Party to terminate this
Agreement in the event that the other Party breaches any obligation of this Agreement, and failure to terminate this Agreement shall not prohibit or modify the recovery of damages pursuant to Section 15.5.

  
 36 

  

 Confidential Treatment Requested by Vera Therapeutics, Inc. 

Pursuant to 17 C.F.R. § 200.83 
  

	12.4	 Rights Upon Bankruptcy. All rights and licenses granted under or pursuant to this Agreement are, and
shall otherwise be deemed to be, for purposes of Section 365(n) of Title 11 of the United States Code and other similar laws in any jurisdiction, licenses of rights to “intellectual property” as defined under such laws.

  

	13.	 REPRESENTATIONS, WARRANTIES AND COVENANTS 

 

	13.1	 Representations and Warranties by Each Party. Each Party represents and warrants to the other as of the
Effective Date that: 

  

	 	(a)	 it is a corporation duly organized, validly existing, and in good standing under the laws of its
jurisdiction of formation; 

  

	 	(b)	 it has full corporate power and authority to execute, deliver, and perform this Agreement, and has taken
all corporate action required by law and its organizational documents to authorize the execution and delivery of this Agreement and the consummation of the transactions contemplated by this Agreement; 

 

	 	(c)	 this Agreement constitutes a valid and binding agreement enforceable against it in accordance with its
terms, except as enforceability may be limited by bankruptcy, fraudulent conveyance, insolvency, reorganization, moratorium and other laws relating to or affecting creditors’ rights generally and by general equitable principles and public
policy constraints (including those pertaining to limitations and/or exclusions of liability, competition laws, penalties and jurisdictional issues including conflicts of laws); 

 

	 	(d)	 all consents, approvals and authorizations from all governmental authorities or other Third Parties
required to be obtained by such Party in connection with this Agreement have been obtained; 

  

	 	(e)	 the execution and delivery of this Agreement and all other instruments and documents required to be
executed pursuant to this Agreement, and the consummation of the transactions contemplated hereby do not and will not (i) conflict with or result in a breach of any provision of its organizational documents;
(ii) result in a breach of any agreement to which it is a party; or (iii) violate any Applicable Law; and 

  

	 	(f)	 neither such Party nor, to the knowledge of the associates of such Party responsible for such matters,
any employee, agent or subcontractor of such Party involved or to be involved in the research, Development or Commercialization of the Antibodies or the Products has been debarred under Subsection (a) or (b) of Section 306 of the Federal
Food, Drug and Cosmetic Act (21 USC §§ 335a) (the “FDC Act”), and upon any discovery thereof, such Person shall be removed from performing under this Agreement. 

  
 37 

  

 Confidential Treatment Requested by Vera Therapeutics, Inc. 

Pursuant to 17 C.F.R. § 200.83 
  

	13.2	 Covenants by Company. Company covenants that: 

 

	 	(a)	 no Person who is known by Company (i) to have been debarred under Subsection (a) or (b)
of Section 306 of the FDC Act, or (ii) to be on any of the FDA clinical investigator enforcement lists will be employed by or on behalf of Company or its Affiliates or otherwise participate in the performance of any activities
hereunder; 

  

	 	(b)	 Company will, prior to its initiation of any clinical trials in any country in the Territory, maintain
an insurance policy that is customary for similarly situated companies in such country to address claims that could reasonably arise from the research, Development, Manufacture, and Commercialization of the Antibodies or Products (and in any event,
with combined limits of not less than [***]. At Novartis’ written request, Company will provide Novartis with evidence of Company’s insurance. Company will provide to Novartis at least [***] prior written notice of any change to
Company’s insurance program that is not consistent with Company’s obligations hereunder or cancellation to Company’s insurance program; and 

  

	 	(c)	 Company will conduct its research, Development, Manufacture, and Commercialization activities relating
to the Antibodies or Products in accordance with Applicable Law (including data privacy laws, current international regulatory standards, including, as applicable, GMP, GLP, GCP, and other rules, regulations and requirements), and will cause any
collaborators and sublicensees to comply with such Applicable Laws. 

  

	13.3	 Representations and Warranties by Novartis. Novartis represents and warrants to Company as of the
Effective Date that: 

  

	 	(a)	 To the knowledge of the Novartis associates responsible for such matters, Exhibit B sets forth an
accurate summary of all Know-How Controlled by Novartis or its Affiliates as of the Effective Date that relates primarily to any Antibody or Product, including the use thereof in the Field, and is reasonably
necessary for the research, Development or Commercialization of any Antibody or Product; 

  

	 	(b)	 Exhibit C sets forth an accurate list of all Patent Rights Controlled by Novartis or its
Affiliates as of the Effective Date that claim any Antibody, any Product or any high-affinity monoclonal antibody against BK virus protein VP1 that was identified or developed by or on behalf of Novartis or its Affiliates on or prior to the
Effective Date, or the use thereof, or are necessary for the research, Development, or Commercialization of any Antibody or any Product; 

  

	 	(c)	 Exhibit F sets forth a true, complete, and correct list of all Regulatory Filings and Regulatory
Approvals Controlled by Novartis or its Affiliates solely relating to any Antibody or Product; 

  

	 	(d)	 Novartis is the sole and exclusive owner, or exclusive licensee of all the rights, title and interest in
and to all Novartis Technology and Manufacturing Technology free from any encumbrance; 

  
 38 

  

 Confidential Treatment Requested by Vera Therapeutics, Inc. 

Pursuant to 17 C.F.R. § 200.83 
  

	 	(e)	 Novartis has not received, nor do the associates of Novartis responsible for such matters have knowledge
of, any written claims or allegations that (i) the research, Development or Commercialization of any Antibody or any Product infringes the Patent Rights or misappropriates the know-how of any Third
Party, (ii) a Third Party has any right or interest in or to the Novartis Technology, or (iii) any of the Novartis Patents are invalid or unenforceable; 

 

	 	(f)	 to the knowledge of the associates of Novartis responsible for such matters, there are no activities by
Third Parties that would constitute infringement of the Novartis Patents or misappropriate of the Novartis Know-How; 

  

	 	(g)	 Novartis has not initiated or been involved in any proceedings or Claims in which it alleges that any
Third Party is or was infringing or misappropriating any Novartis Technology; 

  

	 	(h)	 Novartis has filed and prosecuted patent applications within the Novartis Patents in good faith and
complied with all duties of disclosure with respect thereto; 

  

	 	(i)	 Novartis has taken reasonable precautions to preserve the confidentiality of the non-public information within the Novartis Know-How; 

  

	 	(j)	 Novartis has not entered into a government funding relationship that would result in rights to any
Antibody, Product or any Novartis Patents residing in the US Government, National Institutes of Health, National Institute for Drug Abuse or other agency, and the licenses granted hereunder are not subject to overriding obligations to the US
Government as set forth in 35 USC §§ 200 to 204, as amended, or any similar obligations under the laws of any other country; 

  

	 	(k)	 Novartis has the right to grant to Company the licenses and rights under Section 2.1 and
Section 4.1(d) that it purports to grant hereunder; and 

  

	 	(l)	 Novartis has not granted rights to any Third Party under the Novartis Technology or the Manufacturing
Technology that conflict with the rights granted to Company hereunder, and has not taken any action that would prevent it from granting the rights granted to Company under this Agreement, or that would otherwise materially conflict with or interfere
or limit the rights granted to Company under this Agreement. 

 For purposes of this Section 13.3, “knowledge of
the associates of Novartis responsible for such matters” includes the knowledge of Novartis’ employees performing the functions of regulatory, CMC, clinical, and intellectual property with respect to Antibodies and Products. 

 

	13.4	 Covenants of Novartis. Novartis covenants that: 

 

	 	(a)	 Novartis will not, during the Agreement Term, grant any interest in the Novartis Technology or
Manufacturing Technology that conflict with the rights granted to Company hereunder, and will not take any action that would prevent it from granting the rights granted to Company under this Agreement or that would otherwise materially conflict with
or adversely affect the rights granted to Company under this Agreement; and 

  
 39 

  

 Confidential Treatment Requested by Vera Therapeutics, Inc. 

Pursuant to 17 C.F.R. § 200.83 
  

	 	(b)	 if, at any time after execution of this Agreement, the associates of Novartis responsible for such
matters obtain knowledge that Novartis or any employee, agent or subcontractor of Novartis who participated in the research, Development or Manufacture of an Antibody or Product is on, or is being added to the FDA’s Disqualified/Restricted List
or to any of the FDA clinical investigator enforcement lists, it will provide written notice of this to Company promptly following this fact becoming known to it. 

For purposes of this Section 13.4, “FDA’s Disqualified/Restricted List” is the list of clinical
investigators restricted from receiving investigational drugs, biologics, or devices if the FDA has determined that the investigators have repeatedly or deliberately failed to comply with regulatory requirements for studies or have submitted false
information to the study sponsor or the FDA. 
  

	13.5	 Additional Representations and Warranties by Novartis. Novartis represents and warrants to
Company that the information with respect to the Manufacture of any Antibody Material set forth in any certificate of analysis delivered to Company pursuant to Section 6.3(c) is complete, true and accurate. 

 

	13.6	 No Other Warranties. EXCEPT AS EXPRESSLY STATED IN THIS SECTION 13, (A) NO
REPRESENTATION, CONDITION OR WARRANTY WHATSOEVER IS MADE OR GIVEN BY OR ON BEHALF OF NOVARTIS OR ITS AFFILIATES OR COMPANY OR ITS AFFILIATES; AND (B) ALL OTHER REPRESENTATIONS, CONDITIONS AND WARRANTIES WHETHER ARISING BY
OPERATION OF LAW OR OTHERWISE ARE HEREBY EXPRESSLY EXCLUDED, INCLUDING ANY CONDITIONS AND WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE OR NON-INFRINGEMENT. 

 

	14.	 INDEMNIFICATION; LIABILITY 

 

	14.1	 Indemnification by Novartis. Novartis will indemnify and hold Company, its Affiliates, and their
respective officers, directors and employees (“Company Indemnitees”) harmless from and against any and all Losses incurred by or imposed upon the Company Indemnitees or any of them in connection with any Claim, in each case, to the
extent arising or resulting from: 

  

	 	(a)	 the research, Development, Manufacture or Commercialization of Terminated Products by or on behalf of
Novartis, its Affiliates, or its sublicensees, including all product liability claims (whether arising during research, Development, Manufacture or Commercialization) relating to any Terminated Product (whether pursuant to design defect,
manufacturing defect, failure to notify, or otherwise); 

  

	 	(b)	 the breach of any of the obligations, covenants, warranties or representations made by Novartis to
Company under this Agreement; or 

  
 40 

  

 Confidential Treatment Requested by Vera Therapeutics, Inc. 

Pursuant to 17 C.F.R. § 200.83 
  

	 	(c)	 the gross negligence or willful misconduct of Novartis or any of its Affiliates in performing activities
under this Agreement; 

 provided, however, that Novartis will not be obliged to so indemnify and hold harmless the
Company Indemnitees for any Claims for which Company has an obligation to indemnify Novartis Indemnitees pursuant to Section 14.2 or to the extent that such Claims arise from the breach, gross negligence or willful
misconduct of Company or the Company Indemnitees. 
  

	14.2	 Indemnification by Company. Company will indemnify and hold Novartis, its Affiliates, and their
respective officers, directors and employees (“Novartis Indemnitees”) harmless from and against any and all Losses incurred by or imposed upon the Novartis Indemnitees or any of them in connection with any Claim, in each case, to
the extent arising or resulting from: 

  

	 	(a)	 the research, Development, Manufacture or Commercialization of Antibodies or Products by or on behalf of
Company, its Affiliates, or its sublicensees, including all product liability claims (whether arising during research, Development, Manufacture or Commercialization) relating to any Antibody or Product (whether pursuant to design defect,
manufacturing defect, failure to notify, or otherwise); 

  

	 	(b)	 the gross negligence or willful misconduct of Company or any of its Affiliates in performing activities
under this Agreement; or 

  

	 	(c)	 the breach of any of the obligations, covenants, warranties, or representations made by Company to
Novartis under this Agreement; 

 provided, however, that Company will not be obliged to so indemnify and hold
harmless the Novartis Indemnitees for any Claims for which Novartis has an obligation to indemnify Company Indemnitees pursuant to Section 14.1 or to the extent that such Claims arise from the breach, gross negligence or
willful misconduct of Novartis or the Novartis Indemnitees. 
  

	14.3	 Indemnification Procedure. 

 

	 	(a)	 All indemnification claims in respect of a Company Indemnitee or Novartis Indemnitee will be made solely
by Company or Novartis, respectively. 

  

	 	(b)	 A Party seeking indemnification hereunder (“Indemnified Party”) will notify the other
Party (“Indemnifying Party”) in writing reasonably promptly after the assertion against the Indemnified Party of any Claim or fact in respect of which the Indemnified Party intends to base a claim for indemnification hereunder
(“Indemnification Claim Notice”), but the failure or delay to so notify the Indemnifying Party will not relieve the Indemnifying Party of any obligation or liability that it may have to the Indemnified Party, except to the extent
that the Indemnifying Party demonstrates that its ability to defend or resolve such Claim is materially and adversely affected thereby. The Indemnification Claim Notice will contain a description of the Claim and the nature and amount of the Claim
(to the extent that the nature and amount of such Claim is known at such time). Upon the request of the Indemnifying Party, the Indemnified Party will furnish promptly to the Indemnifying Party copies of all correspondence, communications and
official documents (including court documents) received or sent in respect of such Claim. 

  
 41 

  

 Confidential Treatment Requested by Vera Therapeutics, Inc. 

Pursuant to 17 C.F.R. § 200.83 
  

	 	(c)	 Subject to the provisions of Sections (d) and (e) below, the Indemnifying Party will
have the right, upon written notice given to the Indemnified Party within [***] after receipt of the Indemnification Claim Notice to assume the defense and handling of such Claim, at the Indemnifying Party’s sole expense, in which case the
provisions of Section 14.3(e) below will govern. The assumption of the defense of a Claim by the Indemnifying Party will not be construed as acknowledgement that the Indemnifying Party is liable to indemnify any indemnitee
in respect of the Claim, nor will it constitute a waiver by the Indemnifying Party of any defenses it may assert against any Indemnified Party’s claim for indemnification. In the event that it is ultimately decided that the Indemnifying Party
is not obligated to indemnify or hold an Indemnified Party harmless from and against the Claim, the Indemnified Party will reimburse the Indemnifying Party for any and all costs and expenses (including attorneys’ fees and costs of suit) and any
losses incurred by the Indemnifying Party in its defense of the Claim. If the Indemnifying Party does not give written notice to the Indemnified Party, within [***] after receipt of the Indemnification Claim Notice, of the Indemnifying Party’s
election to assume the defense and handling of such Claim, the provisions of Section 14.3(f) below will govern. 

  

	 	(d)	 Upon assumption of the defense of a Claim by the Indemnifying Party: (i) the Indemnifying
Party will have the right to and will assume sole control and responsibility for dealing with the Claim; (ii) the Indemnifying Party may, at its own cost, appoint as counsel in connection with conducting the defense and handling of such
Claim any law firm or counsel reasonably selected by the Indemnifying Party; (iii) the Indemnifying Party will keep the Indemnified Party informed of the status of such Claim; and (iv) if the Indemnifying Party acknowledges
that it is liable to indemnify an indemnitee in respect of the Claim, the Indemnifying Party will have the right to settle the Claim on any terms the Indemnifying Party chooses; provided, however, that it will not, without the prior written
consent of the Indemnified Party, agree to a settlement of any Claim which could lead to liability or create any financial or other obligation on the part of the Indemnified Party for which the Indemnified Party is not entitled to indemnification
hereunder or which admits any wrongdoing or responsibility for the claim on behalf of the Indemnified Party. The Indemnified Party will cooperate with the Indemnifying Party and will be entitled to participate in, but not control, the defense of
such Claim with its own counsel and at its own expense. In particular, the Indemnified Party will furnish such records, information and testimony, provide witnesses and attend such conferences, discovery proceedings, hearings, trials and appeals as
may be reasonably requested in connection therewith. Such cooperation will include access during normal business hours by the Indemnifying Party to, and reasonable retention by the Indemnified Party of, records and information that are reasonably
relevant to such Claim, and making the Indemnified Party, the Indemnitees and its and their employees and agents available on a mutually convenient basis to provide additional information and explanation of any records or information provided.

  
 42 

  

 Confidential Treatment Requested by Vera Therapeutics, Inc. 

Pursuant to 17 C.F.R. § 200.83 
  

	 	(e)	 If the Indemnifying Party does not give written notice to the Indemnified Party as set forth in
Section 14.3(d) or fails to conduct the defense and handling of any Claim in good faith after having assumed such, the Indemnified Party may, at the Indemnifying Party’s expense, select counsel reasonably acceptable to
the Indemnifying Party in connection with conducting the defense and handling of such Claim and defend or handle such Claim in such manner as it may deem appropriate. In such event, the Indemnified Party will keep the Indemnifying Party timely
apprised of the status of such Claim and will not settle such Claim without the prior written consent of the Indemnifying Party, which consent will not be unreasonably withheld. If the Indemnified Party defends or handles such Claim, the
Indemnifying Party will cooperate with the Indemnified Party, at the Indemnified Party’s request but at no expense to the Indemnified Party, and will be entitled to participate in the defense and handling of such Claim with its own counsel and
at its own expense. 

  

	 	(f)	 In the case of any Infringement Claim, this Section 14.3 shall be subject to
the provisions of Section 9.8. 

  

	14.4	 Mitigation of Loss. Each Indemnified Party will take and will procure that its Affiliates take all such
reasonable steps and action as are necessary or as the Indemnifying Party may reasonably require in order to mitigate any Claims (or potential Losses) under this Section 14. Nothing in this Agreement will or will be deemed to relieve any
Party of any common law or other duty to mitigate any Losses incurred by it. 

  

	14.5	 Special, Indirect and Other Losses. NO PARTY NOR ANY OF SUCH PARTY’S AFFILIATES SHALL BE LIABLE IN
CONTRACT, TORT, NEGLIGENCE BREACH OF STATUTORY DUTY OR OTHERWISE FOR ANY SPECIAL, INDIRECT, INCIDENTAL, PUNITIVE OR CONSEQUENTIAL DAMAGES OR FOR ANY ECONOMIC LOSS OR LOSS OF PROFITS SUFFERED BY THE OTHER PARTY, EXCEPT TO THE EXTENT ANY SUCH DAMAGES
ARE REQUIRED TO BE PAID TO A THIRD PARTY AS PART OF A CLAIM FOR WHICH A PARTY PROVIDES INDEMNIFICATION UNDER THIS ARTICLE 14 OR RESULT FROM EITHER PARTY’S BREACH OF ARTICLE 10. 

 

	15.	 GENERAL PROVISIONS 

 

	15.1	 Assignment. No Party may assign its rights and obligations under this Agreement without the other
Party’s prior written consent, except that (i) either Party may, without such consent, assign its rights and obligations under this Agreement or any part hereof to one or more of its Affiliates; and (ii) either Party
may, without such consent, assign its rights and obligations under this Agreement or any part hereof to a successor to all or substantially all of its business or assets to which this Agreement relates or to which any Antibody or Product relates.
Any permitted assignee will assume all applicable obligations of its assignor under this Agreement. Any attempted assignment in contravention of the foregoing will be void. Subject to the terms of this Agreement, this Agreement will be binding upon
and inure to the benefit of the Parties and their respective successors, heirs and permitted assigns. 

  

	15.2	 Extension to Affiliates. Each Party will have the right to extend the rights, immunities and obligations
granted in this Agreement to one or more of its Affiliates. All applicable terms 

  
 43 

  

 Confidential Treatment Requested by Vera Therapeutics, Inc. 

Pursuant to 17 C.F.R. § 200.83 
  

	 	
and provisions of this Agreement will apply to any such Affiliate to which this Agreement has been extended to the same extent as such terms and provisions apply to such Party. The Party so
extending the rights, immunities and obligations granted in this Agreement will remain primarily liable for any acts or omissions of its Affiliates. 

  

	15.3	 Severability. Should one or more of the provisions of this Agreement become void or unenforceable as a
matter of law, then this Agreement will be construed as if such provision were not contained herein and the remainder of this Agreement will be in full force and effect, and the Parties will use their Commercially Reasonable Efforts to substitute
for the invalid or unenforceable provision a valid and enforceable provision which conforms as nearly as possible with the original intent of the Parties. 

  

	15.4	 Governing Law and Jurisdiction. This Agreement will be governed by and construed under the laws
of the State of New York, USA, without giving effect to the conflicts of laws provision thereof. The United Nations Convention on Contracts for the International Sale of Goods (1980) will not apply to the interpretation of this
Agreement. 

  

	15.5	 Dispute Resolution.

 

	 	(a)	 In the event of a dispute under this Agreement, the Parties will refer the dispute to the Alliance
Managers for discussion and resolution. If the Alliance Managers are unable to resolve such a dispute within [***] of the dispute being referred to them, either Party may require that the Parties forward the matter to the Senior Officers (or
designees with similar authority to resolve such dispute), who will attempt in good faith to resolve such dispute. If the Senior Officers cannot resolve such dispute within [***] of the matter being referred to them, either Party may initiate the
arbitration proceeding outlined in Section 15.5(b) to resolve the matter. 

  

	 	(b)	 Subject to Section 15.16, any unresolved disputes between the Parties relating
to, arising out of or in any way connected with this Agreement or any term or condition hereof, or the performance by either Party of its obligations hereunder, whether before or after termination of this Agreement, shall be referred to and finally
resolved by arbitration. Whenever a Party decides to institute arbitration proceedings, it will give written notice to that effect to the other Party. The seat of arbitration shall be located in New York, New York, in accordance with the arbitration
rules of the International Chamber of Commerce (“ICC”). The arbitration will be conducted by a tribunal of three arbitrators appointed in accordance with ICC rules; provided that
co-arbitrators appointed by each Party will, within [***] of the confirmation of the appointment of the last co-arbitrator, select a third arbitrator as the chair of the
arbitration tribunal. If the two Party-appointed co-arbitrators are unable to select a third arbitrator within such [***], the third arbitrator will be appointed in accordance with ICC rules. The tribunal will
render their award within [***] of the final arbitration hearing. The tribunal shall not have the power to award punitive damages. Decisions of the tribunal will be final and binding on the Parties. Judgment on the award so rendered may be entered
in any court of competent jurisdiction. The Parties each consent to the personal jurisdiction of the U.S. federal courts for any case arising out of or otherwise related to this arbitration, its conduct and its enforcement. The language to be used
in the arbitral proceedings will be English. 

  
 44 

  

 Confidential Treatment Requested by Vera Therapeutics, Inc. 

Pursuant to 17 C.F.R. § 200.83 
  

	 	(c)	 Notwithstanding Sections 15.4 and 15.5(b), any dispute, controversy or claim relating to
the scope, validity, enforceability or infringement of any Patent Right covering the manufacture, use, importation, offer for sale or sale of any Antibody or Product or of any trademark rights relating to any Product shall be submitted to a court of
competent jurisdiction in the country in which such Patent Right or trademark rights were granted or arose. 

  

	 	(d)	 Each Party shall be responsible for all of its costs and expenses incurred with respect to any
arbitration, litigation or other dispute resolution undertaken in accordance with this Agreement. 

  

	15.6	 Force Majeure. In the event that either Party is prevented from performing its obligations under
this Agreement (other than payment obligations) as a result of any contingency beyond its reasonable control (“Force Majeure”), including any actions of governmental authorities or agencies, war, hostilities between nations, civil
commotions, riots, national industry strikes, lockouts, sabotage, shortages in supplies, energy shortages, fire, floods and acts of nature such as typhoons, hurricanes, earthquakes, or tsunamis, the Party so affected will not be responsible to the
other Party for any delay or failure of performance of its obligations hereunder, for so long as Force Majeure prevents such performance. In the event of Force Majeure, the Party immediately affected thereby will give prompt written notice to the
other Party specifying the Force Majeure event complained of, and will use Commercially Reasonable Efforts to resume performance of its obligations. Notwithstanding the foregoing, if such a Force Majeure induced delay or failure of performance
continues for a period of more than [***] either Party may terminate this Agreement upon written notice to the other Party. 

  

	15.7	 Waivers and Amendments. The failure of any Party to assert a right hereunder or to insist upon
compliance with any term or condition of this Agreement will not constitute a waiver of that right or excuse a similar subsequent failure to perform any such term or condition by the other Party. No waiver will be effective unless it has been given
in writing and signed by the Party giving such waiver. No provision of this Agreement may be amended or modified other than by a written document signed by authorized representatives of each Party. 

 

	15.8	 Relationship of the Parties. Nothing contained in this Agreement will be deemed to constitute a
partnership, joint venture, or legal entity of any type between Novartis and Company, or to constitute one as the agent of the other. Moreover, each Party will not construe this Agreement, or any of the transactions contemplated hereby, as a
partnership for any tax purposes. Each Party will act solely as an independent contractor, and nothing in this Agreement will be construed to give any Party the power or authority to act for, bind, or commit the other. 

 

	15.9	 Notices. All notices, consents, waivers, and other communications under this Agreement must be in
writing and will be deemed to have been duly given when: (a) delivered by hand (with written confirmation of receipt); or (b) when received by the addressee, if sent by an internationally recognized overnight delivery service
(receipt requested), in each case to the 

  
 45 

  

 Confidential Treatment Requested by Vera Therapeutics, Inc. 

Pursuant to 17 C.F.R. § 200.83 
  

	 	
appropriate addresses set forth below (or to such other addresses as a Party may designate by notice): 

If to Company: 
 Amplyx
Pharmaceuticals, Inc. 
 12730 High Bluff Drive, Suite 160 

San Diego, CA 92130 

Attn: [***] 
 with a
required copy (which shall not constitute notice) to: 
 Cooley LLP 

4401 Eastgate Mall 
 San Diego,
CA 92121 
 Attn: [***] 

If to Novartis: 
 Novartis
International Pharmaceutical AG 
 Lichtstrasse 35 

CH-4065 Basel 

Switzerland 
 with a required
copy (which shall not constitute notice) to: 
 Novartis Institutes for BioMedical Research, Inc. 

250 Massachusetts Avenue 

Cambridge, MA 02139 USA 

Attn: [***] 
  

	15.10	 Further Assurances. Company and Novartis will execute, acknowledge and deliver any and all such other
documents and take any such other action as may be reasonably necessary to carry out the intent and purposes of this Agreement. 

  

	15.11	 Compliance with Law. Each Party will perform its obligations under this Agreement in accordance with all
Applicable Laws. No Party will, or will be required to, undertake any activity under or in connection with this Agreement which violates, or which it believes, in good faith, may violate, any Applicable Law. 

 

	15.12	 No Third Party Beneficiary Rights. The provisions of this Agreement are for the sole benefit of the
Parties and their successors and permitted assigns, and they will not be construed as conferring any rights to any Third Party (including any third party beneficiary rights), except that the indemnitees expressly identified in
Section 14.1 and Section 14.2 shall be third party beneficiaries of Article 14. 

  

	15.13	 Expenses. Except as otherwise expressly provided in this Agreement, each Party will pay the fees and
expenses of its respective lawyers and other experts and all other expenses and costs incurred by such Party incidental to the negotiation, preparation, execution and delivery of this Agreement. 

  
 46 

  

 Confidential Treatment Requested by Vera Therapeutics, Inc. 

Pursuant to 17 C.F.R. § 200.83 
  

	15.14	 Entire Agreement. This Agreement, together with its Exhibits and schedules, sets forth the entire
agreement and understanding of the Parties as to the subject matter hereof and supersedes all proposals, oral or written, and all other prior communications between the Parties with respect to such subject matter, including the prior confidentiality
agreement. In the event of any conflict between a substantive provision of this Agreement and any Exhibit or schedule hereto, the substantive provisions of this Agreement will prevail. 

 

	15.15	 Counterparts. This Agreement may be executed in two or more counterparts, each of which will be deemed
an original, but all of which together will constitute one and the same instrument. Signatures provided by facsimile transmission or in Adobe Portable Document Format (.pdf) sent by electronic mail shall be deemed to be original signatures.

  

	15.16	 Specific Performance; Cumulative Remedies. Notwithstanding the dispute resolution procedures set
forth in Section 15.5, the Parties hereby expressly recognize and acknowledge that (a) the other Party’s Confidential Information includes highly sensitive trade secret information, (b) breach
of Article 10 by a Party with respect to such information may cause immediate, extensive, and irreparable damage, for which monetary damages would not provide a sufficient remedy, and (c) in such case of breach of Article
10, notwithstanding the intent of the Parties to submit claims to arbitration in accordance with Section 15.5 and without the need to first proceed under Section 15.5, the non-breaching Party shall be entitled to equitable relief (including temporary or permanent restraining orders, specific performance or other injunctive relief) in any court of competent jurisdiction. In addition,
and notwithstanding anything to the contrary set forth in this Agreement, in the event of any other actual or threatened breach hereunder, the aggrieved Party may seek equitable relief (including temporary or permanent restraining orders, specific
performance or other injunctive relief) from any court of competent jurisdiction without first submitting to the dispute resolution procedures set forth in Section 15.5. No remedy referred to in this Agreement is intended
to be exclusive, but each will be cumulative and in addition to any other remedy referred to in this Agreement or otherwise available under Applicable Laws. 

[Signature Page Follows] 

  
 47 

  

 Confidential Treatment Requested by Vera Therapeutics, Inc. 

Pursuant to 17 C.F.R. § 200.83 
  

 License Agreement - Signature Page 

IN WITNESS WHEREOF, the Parties, intending to be bound, have caused this Agreement to be executed and delivered by their duly
authorized representatives. 
  

			
	NOVARTIS INTERNATIONAL PHARMACEUTICAL AG
		
	By:	 	 /s/ Simone Pfirter

	Name:	 	Simone Pfirter
	Title:	 	Authorized Signatory
		
	By:	 	 /s/ Sylvain Beltzung

	Name:	 	Sylvain Beltzung
	Title:	 	Authorized Signatory
	
	AMPLYX PHARMACEUTICALS, INC.
		
	By:	 	 /s/ Ciara Kennedy, Ph.D.

	Name:	 	Ciara Kennedy, Ph.D.
	Title:	 	President and Chief Executive Officer

  

 Confidential Treatment Requested by Vera Therapeutics, Inc. 

Pursuant to 17 C.F.R. § 200.83 
  

 EXHIBIT A 

ANTIBODY 
  

	1.	 GENERAL DESCRIPTION 

[***] 
  

	2.	 AMINO ACID SEQUENCE OF HEAVY AND LIGHT CHAIN 

[***] 

  
 Exhibit A - 1 

  

 Confidential Treatment Requested by Vera Therapeutics, Inc. 

Pursuant to 17 C.F.R. § 200.83 
  

 EXHIBIT B-1 

NOVARTIS KNOW-HOW 

 

	1.	 Presentations 

[***] 
  

	2.	 Technical Research and Development 

 

	 	2.1	 Documents transferred after effective date of the agreement 

{4 pages omitted} 
 [***] 

 

	 	2.2.	 Documents transferred selection of CMO and partially redacted where needed to protect proprietary
quantitative cell culture media compositions 

 [***] 
  

	 	2.3.	 Other Documents 

[***] 
  

	 	2.4.	 Transfer of materials (if any available) 

[***] 
  

	3.	 Pre-Clinical documents 

[***] 
  

	4.	 Clinical 

  

	 	4.1.	 Trial master Files 

{11 pages omitted} 
 [***] 

 

	 	4.2.	 Additional clinical documents 

[***] 
  

	 	4.3.	 Databases (where applicable) 

[***] 

  
 Exhibit B-1 - 1 

  

 Confidential Treatment Requested by Vera Therapeutics, Inc. 

Pursuant to 17 C.F.R. § 200.83 
  

 EXHIBIT B-2 

TRANSFER ASSISTANCE 
 Transfer
documents (redacted where needed) 
 [***] 

Overview of CMC-related Know-How Transfer assistance provided by
Novartis 
 {2 pages omitted} 
 [***] 

  
 Exhibit B-2 - 1 

  

 Confidential Treatment Requested by Vera Therapeutics, Inc. 

Pursuant to 17 C.F.R. § 200.83 
  

 EXHIBIT C 

NOVARTIS PATENTS 
 [***] 

  
 Exhibit C - 1 

  

 Confidential Treatment Requested by Vera Therapeutics, Inc. 

Pursuant to 17 C.F.R. § 200.83 
  

 EXHIBIT D 

ANTIBODY MATERIALS 
 The table
below lists the Inventory Novartis will provide to Company 
 [***] 

  
 Exhibit D - 1 

  

 Confidential Treatment Requested by Vera Therapeutics, Inc. 

Pursuant to 17 C.F.R. § 200.83 
  

 EXHIBIT E 

PROJECT-SPECIFIC CELL BANK 
 The
table below lists the MCB Inventory Novartis will provide to Company’s chosen by Company. 
 [***] 

  
 Exhibit E - 1 

  

 Confidential Treatment Requested by Vera Therapeutics, Inc. 

Pursuant to 17 C.F.R. § 200.83 
  

 EXHIBIT F 

REGULATORY FILINGS AND REGULATORY APPROVALS 

Note 1; the table below does not list all documents nor gives it the same level of detail on document groups in order to keep the table easier to review. All
regulatory documents available to Novartis will be shared. 
 [***] 

  
 Exhibit F - 1

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00339-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00339-of-00352.parquet"}]]